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Proteins that enter the secretory pathway, either soluble or membrane bound, are 
subjected to ER quality control mechanisms: if protein folding is aberrant or 
delayed, proteins are subjected to additional folding cycles or selected for ER-
associated degradation (ERAD). In this process, proteins that fail to reach their 
terminal folding, and thus selected for ERAD, are recognised and retro-
translocated to the cytosol for ubiquitinylation and subsequent degradation by the 
proteasome.  
The most characterised mammalian ubiquitin ligase is HRD1. For its activity HRD1 
needs the interaction with SEL1L an ER resident type I transmembrane 
glycoprotein. SEL1L has been defined as an adaptor protein because, beside its 
interaction with the ubiquitin ligase HRD1, it interacts either with proteins involved 
in substrate recruitment or in the retro-translocation process.  
To induce degradation of specific targets we designed and constructed a new 
class of fusion molecules, termed degradins, where the NH2-terminal part consists 
of a target-specific binding domain, such as an antibody-derived scFv or a ligand 
of a receptor, fused to the COOH-terminal 372 aminoacids of human SEL1L. The 
SEL1L moiety lacks the first NH2-terminal 401 amino acids probably involved in 
identification and recognition of ERAD substrates, but retains the luminal portion, 
homologous to the yeast protein Hrd3p and involved in the interaction with the 
ubiquitin ligase HRD1, and the transmembrane and cytosolic domains. 
By testing the system on two different models (FcεRI-α chain and TGEV spike 
protein S) we found that degradins were able to induce retro-translocation and 
proteasome-mediated degradation of the target. 
To study the retro-translocation induced by degradins, we developed a system 
based on the specific in vivo biotinylation of a reporter engineered by the addition 
of a biotin acceptor peptide (BAP). The BAP peptide is recognised by the cyt-BirA 
enzyme that catalyses the addition of a biotin molecule in the cytosol. Proteins 
normally residing in the ER lumen can get biotinylated only after their dislocation to 
the cytosol. As a model, the MHC-Iα was chosen because target of retro-
translocation induced by US2 or US11 immunoevasins of HCMV; the system 
demonstrated to be very specific and efficient in detecting all types of 
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intermediates of retro-translocation or completely retro-translocated molecules. 
Altogheter, my results strongly suggest that the degradin system can be efficiently 
used to degrade specific target proteins depending on the target recognition 
moiety, moreover our in vivo biotinylation represents a novel and unique method 
for the study of retro-translocation process.  
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List of abbreviations 
 
Ab: antibody 
AD: Alzheimer disease 
APC: antigen presenting cell 
APN: aminopeptidase N  
Apob: apoliprotein B 
APP: amyloid precursor protein 
ATP: adenosine triphosphate 
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Bip: binding protein 
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1 ER quality control: from protein biogenesis to protein degradation 
 
1.1 Protein folding: general aspects 
 
Protein biogenesis is an error prone process due to the high rate of translation, 
cellular stress or nutrient deprivation that can cause incorrect aminoacids 
incorporation.  
Folding efficiency and rate can be compromised by spontaneous errors during 
transcription and translation or by genetic mutations, toxic compounds and cellular 
stress 1,2. 
The resulting aberrant proteins are not able to undergo correct post-translational 
modifications and attain the correct conformation. 
Aberrant proteins represent a threat for the cell because of their possible 
aggregation and precipitation with toxic effects. 
Indeed, many neurodegenerative disorders seem to be linked with defects in 
clearing protein aggregates 3-5. Furthermore there are other human genetic 
diseases, such as autosomal dominant neuroypophyseal diabetes mellitus and 
polyglutammine diseases (spinobulbar muscular atrophy SBMA), that seem to be 
linked with the accumulation of misfolded proteins aggregates, caused by 
deficiency in degradation machinery activity 6. 
These findings have helped to understand the pivotal role of having a functional 
control of protein folding for cell viability. 
To avoid protein aggregation cells have evolved several pathways that target 
defective proteins for proteolysis.  
This process is very important and is underlined by the finding that perhaps 30% 
of newly synthesised polypeptides are destroyed during or soon after translation 7. 
A great number of proteins are sorted for the secretory pathway. These proteins 
can be soluble or membrane anchored and, in both cases, they need to be 
transported through the ER membrane to reach the lumen of ER, in the first case, 
or in order to be inserted in ER membrane, in the second case 8. The vast majority 
of secreted and membrane proteins carry at the N-terminus a cleavable 
hydrophobic domain, the signal sequence that ensures the insertion of the protein 
Introduction  
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in the ER. Translation of secreted or membrane proteins starts in the cytosol since 
the signal sequence emerges from the ribosome and is recognised by signal 
recognition particles (SRP) 9. The complex formed is called Ribosome Nascent 
chain Complex (RNC) and is delivered to the membrane through the interaction 
between SRP and SRP receptor (SR). Afterwards RNC is released to the Sec61 
translocon, SRP and SR dissociate and translation continues pushing the protein 
in the ER lumen through the proteinaceous pore formed by Sec61.  
If the protein contains hydrophobic domains they are inserted into the ER 
membrane from the nascent polypeptide, process ensured by Sec61 10,11. 
The transmembrane domain must be recognised once it arrives inside the channel 
and afterwards it must be released in the lipid phase. The Sec61 channel must 
open in order to allow polypeptide segments to cross the lipid bilayer but it also 
must let hydrophobic segments to pass through its walls to enter into the lipid 
bilayer 12. 
A candidate for being a chaperone that assists membrane protein to be inserted in 
the ER membrane is the Translocating-chain-Associating Membrane Protein 
(TRAM) that spans the ER membrane six times 13 and is located at the front of 
Sec61 channel 12,14.  
To be transported through the secretory pathway, membrane and secretory 
proteins must acquire their proper folding state; acquisition of correct folding is 
possible though the ER Quality Control mechanisms (ERQC) 15.  
ERQC comprises pathways that ensure a protein to acquire the proper folding and 
pathways that make the cell able to detect proteins not properly folded that 
therefore must be degraded. 
The primary mediators of the ER quality control are called chaperones; they 
evaluate substrate conformation and help protein to fold. Chaperones belong to 
different families: the heat shock family includes BiP (HSP70), Erdj (HSP40) and 
GRp90 16, the lectin family includes calnexin, calreticulin and EDEM 17, in addition 
there are chaperones that are substrate specific, like HSP47 18. 
A number of different ER-resident proteins, such as enzymes involved in co- and 
post-translational modifications, were also shown to assist protein folding. 
These enzymes act preventing the formation of aberrant conformations. Some of 
these are enzymes acting on signal sequence cleavage and oligosaccharide 
addition, or they are enzymes that trigger aminoacid isomerisation and oxidation 
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(peptidylprolyl cis-trans isomerase and protein disulphide isomerase, PDI, 
respectively) 19-21. 
Chaperones have two main ways of action: they can stabilise nascent polypeptide 
chains on ribosomes initiating their folding, or they can act downstream translation 
to complete the folding process 22,23. 
Chaperones monitor protein folding through detection of exposed hydrophobic 
patches or through excessive protein dynamics associated with the non compact 
structure characteristic of partially folded proteins 24. 
Hydrophobic domains are commonly buried in folded proteins because of their 
tendency to form insoluble aggregates that can have toxic effects. 
Chaperones such as the heat shock protein Hsp70 (BiP) and chaperonins (Hsp60) 
primarily recognise hydrophobic aminoacid side-chains exposed by non-native 
proteins and promote their folding through ATP-regulated cycles of binding-release 
25,26. 
BiP is a very abundant ER resident chaperone that acts in an early phase binding 
the polypeptide during its traslocation across ER membrane. Its N-terminal portion 
harbors ATPase activity whereas the peptide binding domain is localised at the C-
terminal portion 27,28. 
BiP originally found associated with immunoglobulins 29 is an important player 
during the folding of numerous proteins within the ER. 
BiP is able to bind the substrate after ATP hydrolysis; as different number of 
folding cycles can occur in order to ensure the protein to fold properly, different 
cycles of ATP hydrolysis are essential for substrate binding-release to BiP 30,31. 
Due to the weak ATPase activity of BiP ATP hydrolysis occurs by the help of 
Hsp40 co-chaperone that contain a J domain (ERdj); this domain consists of four 
helices and is essential for the interaction with the ATPase domain of BiP. The 
second helix contains charged and basic residues involved in binding to BiP 31. 
ERdj family comprises five proteins identified, so far, and among them ERdj5 
displays oxidoreductase activity. 
ERdj5 binds Bip via its DnaJ domain and contains four PDI-like domains that 
explain its activity in reducing disulphide bonds of misfolded proteins and its 
activity in preventing protein aggregation 32. 
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Through its binding to BiP Erdj5 probably creates a link between the two different 
activities of BiP in promoting the proper folding of proteins and in removing 
misfolded proteins. 
Intramolecular and intermolecular disulphide bonds are important for the 
stabilisation of tertiary and quaternary structure of proteins. The oxidising 
environment supplied by the ER compartment favours the formation of disulphide 
bonds; this process is catalysed by members of protein disulphide isomerase 
(PDI) family, which possess thiol oxidoreductase activity.  
Oxidative folding occurs through two phases, one co-translational, during which 
intra-molecular disulphide bonds are created between cysteines of the nascent 
chains, and one post-translational, during which disulphide bonds are rearranged 
into the native state. 
The oxidative folding during BiP pathway is displayed by PDI, which is a redox-
driven chaperone participating in the ERAD of several substrates during their 
translation 33. 
PDI catalyses the formation of a disulphide bond in the nascent polypeptide; its 
action is favoured by BiP that keeps the substrate in a conformation that ensure 
PDI to have access to the cysteines involved in a disulphide bond 33. 
If protein folding is delayed, proteins are subjected to additional folding cycles or, 
whether the protein has become irreversibly unfolded, it is addressed to 
proteasomal degradation through ER-associated degradation (ERAD) 34.  
 
1.1.1 Folding of glycoproteins 
 
Several covalent modifications take place in the ER and allow the protein to 
acquire the proper conformation; these modifications include disulphide bond 
formation, N-glycosylation and GPI addition 35. The N-glycosylation is particularly 
important because it allows the interaction with molecular chaperones that assist 
the glycoprotein folding. In fact, the vast majority of proteins that does not acquire 
the correct glycosylation remain in a misfolded state and is degraded. 
Moreover N-linked oligosaccharides addition increases protein solubility, avoiding 
the formation of protein aggregates, and is essential for glycoprotein transport to 
the Golgi apparatus and in general for protein sorting 36. 
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The N-glycosylation provokes binding of a preformed oligosaccaride 
(Glc3Man9GlcNAc2) to asparagine side chains 37. 
The addition of this preformed oligosaccharide occurs as the nascent polypetide is 
inserted in the ER through the Sec61 channel, and is performed by the enzyme 
oligosaccharide transferase 38. 
This synthesis is rapidly followed by the removal of the two outermost glucose 
residues by the enzymes glucosidase I and II 39. 
The removal of terminal glucose residues by glucosidases I and II results in a 
glycoprotein that contains a Glc1Man9GlcNAc2 moiety specifically recognised by 
the lectin-like chaperones calnexin and calreticulin that promote its folding. 
Calnexin and calreticulin are the most extensively studied chaperones with lectin 
activity 40,41. Calnexin is a type I ER membrane protein, while calreticulin is its 
soluble analogue that localises in the ER by a C-terminal KDEL sequence 42,43 
KDEL sequence is responsible of the binding to a membrane bound receptor that 
shuttles from the ER to the Golgi, causing the KDEL containing protein to 
relocalise in the ER compartment 44. 
Following calnexin-calreticulin folding cycle, glucosidase II removes the remaining 
glucose residue; if the resulting protein has been able to reach its proper folding 
can exit from the ER through COPII vesicles that bud from the ER 45,46. If instead, 
the protein is not completely folded, it is recognised because it exposes 
hydrophobic patches or because it harbors an insufficiently compact structure.  
For those proteins that have not been able to reach the correct folding, cycles of 
deglucosylation-reglucosylation take place in the ER mediated by the enzyme 
UDP-glucose glycoprotein glucosyltransferase (UGGT), that adds back a glucose 
residue to the N-linked glycan 47. The resulting monoglucosylated proteins can re-
enter the calnexin-calreticulin cycle because they are specifically recognised by 
these two chaperones 48. Thus, cycles of deglucosylation-reglucosylation make 
possible to restart the protein folding process giving to glycoproteins more 








               Takeda et al Current Opinion in Chemical Biology 2009 
 
Figure 1: A preformed oligosaccaride (Glc3Man9GlcNAc2) is added to asparagine side chains and is 
organised in three branches (A, B and C). Glucosidase I and II remove the two outermost glucose 
residues leading to a monoglucosylated protein, specifically recognised by calnexin and calreticulin 
that promote protein folding. If the protein is not able to reach its proper conformation it can re-
enter the calnexin-calreticulin cycle, by the action of glucosidase II that removes the remaining 
glucose residue, and UGGT that readd a glucose moiety, allowing the protein to be recognised, 
once again, by calnexin and calreticulin. 
 
Oxidative folding during the post-translational phase requires the activity of 
ERp57, a member of the PDI superfamily, that associates with calnexin and 
calreticulin and is involved in glycoprotein quality control 49. ERp57 carries out the 
reduction, isomerisation and oxidation of non-native disulphide bonds similarly to 
PDI but much more slowly 50. 
Calnexin and calreticulin also promote oxidative folding because responsible of the 
retention of misfolded proteins; this activity facilitates the interaction between the 












Figure 2: Cooperation between calnexin, calreticulin and ERp57 in glycoprotein folding. 
Glycoproteins are modified by N-glycosylation, during or soon after translation. Glucosidase I and II 
remove the two outermost glucose residues, the resulting monoglucosylated form is specifically 
recognised by calnexin and calreticulin and enter the folding cycle. ERp57 interact specifically with 
calreticulin promoting protein oxidative folding. Finally glucosidase II removes the remaining 
glucose residues and the protein modified in this way is able to exit ER through COP-II vesicles or 
if not properly folded can re-enter the calnexin-calreticulin cycle. 
 
 
1.2 Disposing of ER proteins 
 
Soluble and membrane proteins that fail in the acquisition of the correct folding 
must be degraded in a process called ER associated degradation (ERAD) 34. 
ERAD takes place after the recognition of the substrate, using as mediators ER 
lectins and molecular chaperones such as BiP. Chaperones and lectins that 
promote protein folding can, on the other side, decide which proteins must be 
targeted to degradation. 
In this process, terminally unfolded or misfolded proteins, upon recognition, are 
retro-translocated to the cytosol, a process also known as dislocation, for 
degradation by the 26S proteasome complex, a proteolytic particle enriched at ER 




For the disposal of misfolded proteins from the ER, removal of α1,2-bonded 
mannose residues from the N-glycan is required as it allows the generation of a 
code deciphered by ERAD machinery 54. 
Mammalian ER α1-2 mannosidase I is a member of GH47 family that contains 
also EDEM 1, 2 and EDEM 3 proteins 17,55,56. EDEM (ER degradation-enhancing α 
mannosidase-like proteins) subfamily has been described as player in substrate 
de-mannosylation 57. 
ER α1-2 mannosidase I and the EDEM family members function sequentially 
leading the protein to expose a terminal α(1,6)-bonded mannose on the glycan 
which is recognised by proteins containing a mannose 6-phosphate receptor 
homology-domain (MRH-domain), Yos9 in yeast and OS-9 and XTP3-B in 
mammals. These proteins, due to the presence of the MRH domain functional in 
oligosaccharide binding 58, function as lectin and promote the recognition of 
misfolded proteins 59. 
 
EDEM1, through its interaction with calnexin, avoid futile calnexin calreticulin 
folding cycles when the protein is already irreversibly unfolded. In addition EDEM1 
accelerates ERAD by preventing the formation of disulphide-bonded dimers or 
covalent aggregation containing misfolded proteins 57. This function is carried out 
by EDEM1 through its specific association with an ER resident member of the 
ERdj family named ERdj5, which catalyses the reduction of disulphide bonds and, 
in turn, recruits BiP preventing aggregation of misfolded proteins and in this way 
promoting ERAD process. 
ERdj5 accelerates ERAD and the model proposed is that once misfolded proteins 
are transferred from calnexin to EDEM, ERdj5 bound to EDEM reduces the 
disulphide bonds of misfolded proteins disaggregating multimeric complexes. At 
the same time ERdj5 keeps the substrate in an unfolded dislocation competent 
state 32,60 and catalyses the conversion of ATP form of BiP into ADP-BiP causing 







Figure 3: ER protein disposal. When a protein becomes irreversibly unfolded the action of ER 
mannosidase I and EDEM generates a signal for ERAD represented by a terminal α(1-6)-bonded 
mannose avoiding, in this way, the protein to re-enter another futile calnexin calreticulin folding 
cycle. The unfolded protein, by the action od EDEM is maintained in an unfolded dislocation 
competent state and therefore can be retro-translocated from the ER to the cytosol. 
 
 
1.3 The unfolded protein response 
 
Accumulation of aberrant proteins results in the induction of the unfolded protein 
response (UPR), an ER-to-nucleus and ER-to-cytosol signalling pathway. The ER-
to-nucleus signalling gives rise to a transcriptional programme which increases 
expression of chaperones and enzymes required for protein modification, ER 
membrane expansion, protein trafficking from the ER and the disposal of 
misfolded proteins, while the ER-to-cytosol signalling results in the attenuation of 
protein synthesis 61. 
Accumulation of misfolded proteins results in BiP dissociation from three ER 
transmembrane proteins that function as UPR transducers: IRE1, PERK and 
ATF6.  
Following dissociation from BiP, ATF6 is transported to the Golgi where it gets 
cleaved by two proteases S1P and S2P 62,63. The cytosolic N-terminal 377 
aminoacids fragment, composed of a basic leucine zipper, becomes an active 
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transcriptional factor that translocates to the nucleus 64-67. The outcome is the 
induction of ER stress response genes 64. 
The UPR transducer IRE1 is a protein kinase and ribonuclease associated to the 
ER membrane that during stress conditions binds to misfolded protein. This 
binding activates IRE1 oligomerisation keeping IRE1 away from Bip and enabling 
its activation by trans-autophosphorylation 68. Activated IRE1 causes, through its 
ribonuclease activity, the splicing of XBP1 mRNA independently from the 
spliceosome. The spliced form of XBP1 mRNA produces a protein that activates 
the transcription of its target genes 69. 
UPR induced genes encode for proteins involved in different steps of ERAD; 
proteins acting in the recognition and in the ER-to-cytosol dislocation of misfolded 
proteins. The spliced form of XBP1, in particular, targets genes expressing 
proteins involved in ER protein disposal 69. 
The ER-to-cytosol signalling of UPR decreases the rate of protein translation by 
the activity of the transmembrane protein kinase PERK that contains a cytosolic 
kinase activity. PERK, under ER stress conditions and upon dissociation from BiP, 
catalyses its autophosphorylation and activation 70, once activated, PERK is able 
to block protein synthesis, catalysing the phosphorylation of the translation 
initiation factor eIF2α 71. 
A prolonged UPR signalling can lead to cell death, through induction of apoptosis. 
In particular, IRE1 dependent unfolded protein response seems to be anti-
















                         Douglas M. Cyr & Daniel N. Hebert Embo reports 2009 
                       
Figure 4: Unfolded protein response pathway. Unfolded protein accumulation causes BiP to 
disassociate from IRE1, PERK and ATF6 UPR transducers. Following the release of BiP IRE1 can 
catalyse it autophosphorylation and get activated. Activated IRE1 promotes alternative splicing of 
XBP1 mRNA leading to XBP1 protein product that can translocate to the nucleus and act as a 
transcription factor  
Also PERK catalyses its autophosphorylation, upon release of BiP, and subsequently it catalyses 
elF2α phosphorylation  
ATF6 upon release of BiP is processed leading to release of its cytosolic portion that is now able to 
translocate in the nucleus and activate expression of UPR genes. 
 
 
1.4 Ubiquitin proteasome system  
 
The main protein degradation activity in the cell is carried out by the ubiquitin-
proteasome system 73-75. 
For proteasomal degradation proteins need to be ubiquitinylated through the 
participation of different ubiquitin ligases whose catalytic domain is always 
localised in the cytosol even if the ligase is anchored to the ER membrane 76. 
Once recognised, proteins that must be degraded are targeted to the proteasome, 
which is a multisubunit with proteolytic activitiy shielded from cytoplams and 
nucleoplasm, in order to highly regulate proteolysis and to avoid non-selective 
protein degradation 77. Protein degradation is a highly specific process, proteins 
have different half-lifes that range from minutes to years. This diversity in protein 
half-life ensures the right concentration of proteins within the cell; a balance 
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between synthesis and degradation rates is essential because the concentration of 
a protein determines its biological activity. 
Proteasomal degradation requires energy in part for protein unfolding which 
confers to the protein the capability to access the proteolytic activity of the 
proteasome. The specificity of the degradation process is vastly provided by 
protein polyubiquitination that enables proteasomal recognition. 
Ubiquitin proteasome system (UPS) controls cell cycle progression, signal 
transduction, cell death, immune responses, metabolism, protein quality control 
and development through degradation of short lived regulatory or structurally 
aberrant proteins 78,79. Ubiquitin dependent proteolysis is fundamental in the 
adaptive immune response, because it leads to the production of peptides that can 
be presented on the major hystocompatibility complex (MHC) class I antigen 
presentation pathway. Peptides derived from proteasomal degradation of non-self 
antigens can be loaded on MHC class I molecules and presented to CD8+ 




Ubiquitin is a 76 aminoacids long protein that plays its main role in misfolded 
protein degradation, but also in many different cellular processes, by its covalent 
conjugation to cellular proteins 80-82. 
Ubiquitinylation proceeds through the formation of a covalent amide bond between 
the C-terminal glycine residue of ubiquitin and the ε amino group of a lysine 
residue of the substrate 74,83. Upon attachment on the lysine of the substrate, the 
ubiquitin becomes substrate for the attachment of another ubiquitin molecule.  
In spite of the presence in the ubiquitin polypeptide sequence of seven lysines, all 
potentially involved in chain formation, mainly Lys48 and Lys63 are well-
characterised residues involved in ubiquitinylation in vivo 83. 
Proteins can be modified with polymers of ubiquitin that can display both 
proteolytic and non-proteolytic functions, depending on the conformation of the 
polyubiquitin chains, or with ubiquitin monomers, which is always connected to 
non-proteolytic processes 84. 
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Monomers of ubiquitin can bind to the target as single moiety 
(monoubiquitinylation) or as multiple single moieties (multiple 
monoubiquitinylation) 85. 
Monoubiquitinylation can alter protein activity and localisation; it is mainly 
associated with sorting of proteins, viral budding and membrane trafficking due to 
its role in endocytosis 86,87. 
Polyubiquitinylation that involves Lys48 is associated with a degradative fate, 
whereas Lys63 (although it has been recently described as a target for 26S 
proteasome 88) is generally associated with non-degradative fate.  
Lys63 polyubiquitinylation acts during DNA repair, kinase signalling 89, intracellular 
protein trafficking 90 and transcription 91. 
Through the targeting of proteins for proteasomal degradation, Lys48 
polyubiquitinylation plays an essential role in the regulation of cell cycle, immune 
signalling, DNA repair and apoptosis by controlling the abundance of cell cycle 




Figure 5: Schematic representation of different types of ubiquitinylation. A) The substrate can be 
modified with a monomer of ubiquitin (monoubiquitylation), with multiple monomers of ubiquitin 
(multi-monoubiquitinylation) or with ubiquitin chains (polyubiquitinylation). B) The most common 
lysine residues involved in the formation of polyubiquitin chains are Lys48, associated with 





Basically the ubiquitinylation mediated degradation requires the activity of three 
enzymes: E1, E2 and E3. The process occurs through the following steps: 
1. The E1 enzyme activates ubiquitin by hydrolysing a molecule of ATP 
establishing a thioester bridge between the cysteine in the active centre of E1 
and the glycine 76 of the ubiquitin carboxy terminus. Different E1 enzymes are 
present in the cytosol and in the nucleus 92. 
2. The activated ubiquitin is transferred to a member of ubiquitin conjugating 
enzyme family E2 (or Ubc) with the same thioester bond. E2 enzymes can be 
divided in groups; every group has the specificity for a particular set of E3 
enzymes. 
3. E3 enzymes recognise target proteins that must be degraded and are able to 
interact with E2 enzymes. E3-target complexes recognise E2-ubiquitin 
complexes and this interaction allows the transfer of ubiquitin from the E2 
enzyme to the target 93. 
4. The E3 enzyme releases the ubiquitinylated protein 
5. These steps are repeated until a chain of at least four ubiquitin subunits is 
attached to the target. In some cases polyubiquitinylation is obtained by the 
activity of ubiquitin elongating factors termed E4 enzymes 94. 
 
E3 enzymes possess the ability to ligate activated ubiquitin molecules to the 
substrate; there are several E3 enzymes and the way of action can be very 
different. 
Based on their structure E3 enzymes can be assigned in two groups: the HECT 
(homology to E6AP C-terminus) E3s and the RING finger E3s, which are in turn 
subdivided in two families, the U-box 95,96 and the classic RING fingers.  
The RING finger is characterised by the presence of cysteines and histidines that 
bind to zinc ions allowing the structure to be stabilised, the U-box, instead, share 
the same pattern of aminoacid residues but do not contains the series of cysteines 
and histidines and the structure is probably stabilized by salt-bridges and 
hydrogen bonds. 
The RING finger E3s bind both the substrate protein and the E2 enzyme bound to 
ubiquitin and catalyses the direct transfer of ubiquitin to the substrate, whereas, for 
HECT E3s pathway is different; after E3 binding to both substrate and E2 enzyme, 
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ubiquitin is transferred first form E2 enzyme to an internal active cysteine residue 
of HECT E3 enzyme and then to the substrate’s lysine 97. 
RING finger E3s are susceptible to auto-ubiquitinylation and this causes their short 
half-life. HRD1, which is the best known E3 enzyme, requires the interaction with 
an adaptor protein, the ER resident protein SEL1L, for its stabilisation, otherwise it 
catalyses its auto-degradation 98. 
In order to be target for 26S proteasomal degradation proteins must be 
polyubiquitinylated with at least four molecules of ubiquitin 99. 
The ubiquitin chain is recognised by 26S proteasome complex, then it is inserted 
into the catalytic side where a series of proteases rapidly degrade the protein into 
small peptides 100. 
Ubiquitinylation is also essential for the process of dislocation of proteins from the 
ER to the cytoplams. Disruption of ubiquitinylation machinery causes an inhibition 
of protein dislocation 101-103. 
In addition to ubiquitin there are other members of the family of ubiquitin-like 
modifiers (UBL), such as SUMO 1, 2 and 3, Nedd8 and ISG15. Several UBLs 
have been described to modify proteins following an enzymatic pathway similar of 
that of ubiquitin 104,105. 
Ubiquitin like modifiers intervene in the regulation of several cellular processing, 
such as transcription, DNA repair, autophagy and cell cycle control.  
Among a long list of poorly studied UBLs Fat10 is the only one that seems to be 
involved in substrate degradation in an ubiquitin independent manner 106. 
 
 
Figure 6: Through the hydrolysis of ATP E1 enzyme activates the ubiquitin and establishes a 
thioester bond with glycine 76 residue of ubiquitin C-terminus. Once activated, ubiquitin is 
transferred to E2 enzyme . E3 enzyme binds to the E2 enzyme and catalyses the tranfer of 
ubiquitin from E2 to the substrate that it recognises specifically. Polyubiquitinylated proteins are 
targets of proteasomal degradation. 
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1.4.2 The proteasome  
 
The 26S proteasome is a large protein complex responsible for intracellular protein 
degradation, a process that requires energy. The proteasome contains in fact an 
ATP-dependent protease that collaborates with the ubiquitin system. Proteasome 
complex is composed by the catalytic subunit 20S of about 750 kDa and the 19S 
regulatory subunit of about 700 kDa 107-109. This regulatory subunit can bind to one 
or both sides of 20S subunit in order to form an enzymatically active proteasome 
that could be the so-called 26S or 30S complexes. In the case of the 26S, only 
one 19S subunit is bound, while in the case of 30S proteasome, both sides of 20S 
subunit are bound by the 19S subunit 110.  
The role of the 19S subunit is to recognise ubiquitinylated proteins and probably it 
also plays a role in substrate unfolding and transfer to the 20S catalytic subunit. 
The 20S proteasome is a barrel shaped structure build up of four rings; two β rings 
form the inner proteolytic chamber while two α rings constitute the outer part of the 
proteasome. 
Each ring of both yeast and mammalian 20S proteasome contains seven different 
α subunits α1-7 or seven different β subunits β1-7 giving rise to hetero-heptameric 
rings.  
Proteolytic activity is carried out by the innermost part of proteasome, which 
constitute the main chamber, whereas α rings regulate the access of substrate 
within the catalytic core.  
Only subunits β1, β2 and β5 of the main chamber show proteolytic activity, in 
particular, caspase like activity, trypsin-like activity and chimotrypsin-like activity 
respectively 111. 
The release of substrate within the proteasome is regulated by different regulator 
proteins, such as the 11S regulator particle and the ATP dependent 19S regulator 
particle or PA700 112. 
PA700 is composed of about 20 subunits with a size of 25-110 kDa; six of these 
subunits are members of a large protein family characterised by domains 
containing ATP-binding motifs, named the AAA family ATPases, that together with 
two large regulatory components, Rpn1 and Rpn2, form the so-called “base” 113.  
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The base presumably functions as ubiquitin receptor 114 whereas the other sub-
complex of PA700 is called the “lid” and does not present ATPase activity. 
ATPases seem to have the role of continuously supply of energy for protein 
unfolding, to allow the penetration of proteins into the channel of 20S proteasome 
and the subsequent degradation 115,116. 
The base complex of PA700 is bound to the outermost α ring of 20S proteasome 
and is able to open a narrow channel following ATP hydrolysis 117. 
Ubiquitinylated proteins show a steric impediment for the entry into the 
proteasome structure; this implies the necessity of a deubiquitinylation activity 
coordinated with proteasome function 118-120. Deubiquitinylation activity physically 
linked with protease activity of the proteasome is accomplished by lid components 
of PA700 121. 
 
                           Julian Adams Nature Reviews Cancer 2004 
 
Figure 7: Proteasome structure. The 20S catalytic core of the proteasome is build up of four rings; 
the two outermost are α rings whereas the inner part is formed by two β rings that display the 
proteolytic activity. Each α ring contains seven different α subunits and each β ring contains seven 
different β subunits. In order to get activated the proteasome can bind one or two 19S subunits 





Deubiquitinylating enzymes (DUBs) play an essential role in regulating 
proteasomal degradation. Deubiquitinylases (DUBs) are specific proteases that act 
on polymeric ubiquitin by cleavage of the C-terminal glycine of ubiquitin.  
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DUBs are grouped in a large family subdivided in five classes: ubiquitin C-terminal 
hydrolases (UCHs; 122) ubiquitin specific processing proteases (USPs), Josephins 
and JAB1/MPN/MOV34 metalloenzymes (JAMM/MPN+; 123), ovarian tumour 
proteases (OTUs; 124) and JAMM motif (zinc metallo) proteases. The UCH, USP, 
OTU and Josephin families are cysteine proteases whereas JAMM/MPN+ family 
members are zinc metalloproteases 125. 
The main activity of DUBs is the removal of polyubiquitin chains to allow the 
substrate to entry within the proteasome and get degraded. However several other 
functions have been linked to DUBs. 
DUBs can act to recycle ubiquitin contributing to ubiquitin homeostasis, to allow 
the escape of proteins from degradation either proteasomal or lysosomal or to 
control protein trafficking 126,127. DUBs act removing non-degradative signals, 
reversing ubiquitin signalling or in editing of ubiquitin modifications by trimming 
ubiquitin chains 128. 
Substrates that are targeted for proteasomal degradation are recognised by the 
regulator particle of the proteasome. Proteasome associated deubiquitinating 
enzymes can start to shorten the polyubiquitin chain after substrate recognition. 
Lid components have been associated with deubiquitinylating and ubiquitin 
receptor activity.  
In yeast lid complex of PA700 contains Rpn10 and Rpn13 subunits are thought to 
serve as ubiquitin receptors 129-132. Among the other components (Rpn3, Rpn5-9, 
Rpn11-13 and Rpn15) Rpn11 has been described to display metalloprotease 
activity that cleaves peptide bond between the proximal ubiquitin and polyubiquitin 
chain 118,119. 
In mammals yeast homologue of Rpn13 has been discovered and named 
hRpn13/Admr1. hRnp13 recruits UCH37 a previously described deubiquitinylating 
enzyme (DUB) associated with the proteasome 133. Another deubiquitinylating 
enzyme associated with the proteasome is Ubp6 in yeast and Usp14 in mammals. 
Both DUBs are not a constituent component of proteasome structure but they 







1.5 ERAD pathway 
 
The ER associated degradation pathway comprises recognition of misfolded 
proteins, retro-translocation from the ER lumen to the cytosol, polyubiquitinylation 
and proteasomal degradation 134-136. 
Misfolded proteins and non-assembled proteins are retained in the ER bound to 
chaperons such as Hsp70 family, calnexin and calreticulin or by lectins. After 
recognition the misfolded protein initiates the retro-translocation process. 
The retro-translocation of the substrate is an essential process that cause the 
dislocation of the misfolded protein from the ER lumen, where it is recognised to 
the cytoplasm where proteasome is present and degradation can occur.  
The spatial separation of the site of protein folding and the site of degradation, 
confers to the ERAD system an activity specific only for terminally misfolded 
proteins and not for folding intermediates. 
The ER to cytosol dislocation process could occur through a channel that would 
lead misfolded proteins to cross the ER membrane and arrive to the cytosol. A 
putative retro-translocation channel is sec61p in yeast 137 and Sec61 in mammals 
138. 
In mammals Derlin-1, an ER membrane proteins with four transmembrane 
domains, has been described to participate in the retro-translocation process 139. 
In yeast the homologue of Derlin-1, Der1p shows the same topology and although 
it was demonstrated to be essential in misfolded protein degradation a clear 
evidence of its involvement in retro-translocation is missing 140. A further 
hypothesis, that will be described in more details later on, is that proteins would be 
exported from the ER within lipid droplets 141. 
Another open question concerns the organisation of the retro-translocation and 
ubiquitinylation processes. One of the most probable hypothesis is that the protein 
is ubiquitinylated during retro-translocation, and after ubiquitinylation the ATPase 
p97 (cdc48 in yeast) is recruited to the ER membrane to supply the energy 
through ATP hydrolysis, for dislocation or for the release of substrates that have 
been already retro-translocated 142. 
Following release of the misfolded protein the polyubiquitin chain is trimmed by the 
activity of deubiquitinylating enzymes (DUBs), step required to enter inside the 
proteasome. The activity of peptide N-glycanase, that displays deglycosylation 
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activity in the cytosol, could also be required for protein unfolding that is required 
for the efficient release of proteins within the proteasome. 
Substrates are released in the 20S proteasome by the help of an ATP-dependent 
activator known as PA700 or regulatory complex 19S which binds 20S 
proteasome in order to form a complex known as 26S 100,108.  
Once within the 20S catalytic core of the proteasome the substrate is broken down 
into peptides. 
 
Figure 8: ERAD pathway. Misfolded proteins are recognised within the ER by chaperones and 
lectins, once recognised they are committed for degradation. To get degraded by the proteasome 
misfolded proteins must dislocate from the ER to the cytosol probably through a channel or within 
lipid droplets. During retro-translocation the protein is polyubiquitinylated, a step required for the 
recognition by the proteasome. In order to entry within the proteasome steps deglycosylation and 




1.5.1 ERAD in yeast 
 
Several ERAD pathways have been described in yeast and can occur depending 
on the type of the protein and on the localisation of the misfolded moiety. 
Ì) The ERAD-L pathway is activated when soluble, secretory or membrane 
proteins have a defect in their luminal portion; ÌÌ) the ERAD-C pathway is involved 
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when a protein contains defects in the cytoplasmic region; ÌÌÌ) the ERAD-M 
pathway occur when a protein contains a lesion located into the transmembrane 
domain 143,144. 
 
ERAD –L exploits the activity of Hrd1p ubiquitin ligase, which is a RING finger E3 
enzyme that forms a complex with the adaptor protein Hrd3p, responsible of 
substrate recruitment 145,146. 
Hrd1p interacts with the putative retro-translocation channel Der1p through Usa1p 
protein 147. Usa1p is a double-spanning membrane protein that was found to be 
upregulated by the UPR 148 and that mediating the interaction between Hrd1p and 
Der1p seems to create a link between the ubiquitinylation process and dislocation 
to the cytosol 147. 
 
ERAD C requires the activity of the Doa10 ubiquitin ligase, whose activity also 
depends on its RING finger. Doa10 localises at the ER/nuclear envelope, it 
contains 14 transmembrane domains and both its N- and C-termini are facing to 
cytosol, where most of the molecule resides.  
It forms a complex with E2 enzymes Ubc6 and Ubc7, Cue1, a protein that 
stimulates Ubc7 and with Ubx2p, a membrane protein that, in turn, binds the 
ATPase Cdc48 147,149.  
Doa10p targets membrane proteins containing misfolded cytosolic domain toward 
proteasomal degradation 144. 
 
Much less is known about ERAD-M pathway: it seems to depend on Hrd1 
complex, but, differently from ERAD-L, it is independent of Usa1p and Der1p 
144,150,151.  
All these pathways converge to the ATPase cdc48 in order to ensure protein 
dislocation into the cytosol and ubiquitinylation. 
 
 
1.5.1.1 Hrd1p ubiquitin ligase complex in yeast 
 
In yeast ERAD M and ERAD L are carried out by the activity of Hrd1p ubiquitin 
ligase complex. Hrd1p is a multispan ER membrane protein characterised by the 
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presence of two distinct domains, one hydrophobic localised at the N-terminus 
containing the six transmembrane segments, and one hydrophilic localised at the 
C-terminus. The C–terminal portion contains the RING-H2 motif, required for the 
degradative function 145,152. As mentioned before the E2 enzymes responsible of 
soluble and transmembrane protein degradation are Ubc6p and Ubc7p 153. 
Ubc6p is an integral membrane protein while, Ubc7p is recruited to the membrane 
by Cue1p 146,154. 
The activity of the E3 enzyme Hrd1p can be carried out thanks to its interaction 
with the protein Hrd3p 155. Hrd3p is an ER glycoprotein that contains a single 
membrane span localised near the C-terminus and a large N-terminal luminal 
domain with different sets of repeated regions 156,157. 
An essential role of Hrd3p during ERAD is to maintain the stability of Hrd1p 157. 
A number of studies have been performed on Hrd1p and Hrd3p interaction and 
functions in which it was demonstrated that the Hrd1p N-terminal transmembrane 
domain is essential and sufficient for the binding to Hrd3p. Moreover this 
transmembrane region mediates the Hrd3p stabilisation effect on Hrd1p 155. 
Furthermore the Hrd3p domain involved in Hrd1p stabilisation was investigated. 
Hrd3p contains two luminal domains; the first one starts from residue 1 and ends 
with residue 390 and the second one (residues 391-767) shows a high homology 
with the C. elegans protein SEL-1 and murine SEL1L 152,158,159. The C-terminus 
contains the transmembrane region and a short cytosolic tail. 
The main function of Hrd3p is the substrate recognition and the formation of 
complexes with chaperones. 
Both Hrd1 and Hrd3 encoding genes are induced by the IRE1 yeast homologue 
Ire1p UPR transducer 148. 
The Hrd1p complex also contains Yos9p, a lectin that specifically binds to 
misfolded glycoproteins and accelerates ERAD 58,160. Yos9 requires protein 
demannosylation, a signal for protein disposal, in order to bind the substrate 161,162. 
Another protein, Usa1p, was found to be part of the complex and probably it 
assists the clearing of luminally misfolded glycoproteins from the ER, allowing the 
interaction between Der1p and Hrd1p ligase and, therefore, probably linking retro-
translocation and ubiquitinylation processes 58,160,163. Moreover, Usa1p has been 
demonstrated to induce Hrd1p oligomerisation a step that seems to be required for 
protein degradation 164. 
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Another participant of the Hrd1p complex is Kar2p/BiP, which is a component of 
the HSP70 family whose action is keeping misfolded proteins in soluble state 
165,166. 
The Hrd1 complex consists of Hrd3p, Der1p, the ER lectins Yos and BiP; all these 
proteins together form a luminal surveillance complex that is able to recognise 
misfolded proteins and to promote their degradation 150. 
Once recognised by the ER lectins the protein is bound to the ubiquitin ligase, 
subsequently the protein starts to be retro-translocated into the cytosol and the 
process of ubiquitinylation seems to happen concomitantly with the process of 
retro-translocation. 
Extraction of the ubiquitin-modified protein occurs with the assistance of Cdc48 
ATPase and its cofactors Ufd1p and Npl4p; this complex most likely provides the 
energy for pulling proteins out of the ER 167. Alternatively the Cdc48 complex could 
allow the release of already retro-traslocated substrate 168. 
 
1.5.2 ERAD in mammals 
 
ERAD pathways are not described in such a deep detail as in yeast, however 
some homologous proteins have been identified between mammals and yeast. For 
example mammalian homologue of Doa10p, involved in degradation of protein 
bearing cytosolic misfolded domains, has been discovered and named TEB4-
MARCHVI. This protein catalyses its own ubiquitinylation and for this reason it has 
been postulated to act as E3 ubiquitin ligase, although substrates of this predicted 
ubiquitin ligase have not been described so far 169. 
Hrd1p mammalian homologue was also discovered and named HRD1/Synoviolin 
and is, so far, the best E3 enzyme characterised in mammals acting during both 
ERAD-L and ERAD-M pathways 152,170.  
Another well characterised ubiquitin ligase is gp78, which is the first identified ER-
membrane spanning ubiquitin ligase of mammalian cells; it has been shown to 
ubiquitinylate a variety of substrates and interestingly gp78 appears to target all 
substrates of the different pathways ERAD L, M and C 171. 
In addition to the membrane ubiquitin ligases there are also E3 enzymes 172 
involved in ERAD that are located in the cytosol. For example Parkin, a ubiquitin 
ligase with two RING fingers, was identified to mediate ubiquitinylation of Pael-R 
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but it also recognises non ER substrates possibly due to its interaction with 
cytosolic Hsp70 173.  
Another cytosolic E3 implicated in degradation of CFTRΔF508 a mutant of the 
cystic-fibrosis channel, which is retained within the ER and subjected to ERAD, is 
CHIP. CHIP is a U box ubiquitin ligase that function together with cytosolic 
chaperones in protein quality control 174. 
 
1.5.2.1 HRD1/SEL1L ubiquitin ligase complex in mammals 
 
Among the different identified mammalian E3 ligases, the best characterised one 
is HRD1/synoviolin, a 671 amino acid long ER transmembrane resident protein 
with six transmembrane segments and a RING finger motif localised to the 
cytosolic side. It is also characterised by the presence of a proline-rich cluster not 
found in yeast 175. 
HRD1 displays an ubiquitinylation activity by means of its catalytic RING finger, 
which in vitro catalyses the transfer of ubiquitin from E2 enzymes to substrates or 
its self-ubiquitinylation 176. 
HRD1 interacts specifically with the E2 enzyme UBC7 and its activity is restricted 
to Lys48 polyubiquitinylation 175. 
A protein found to interact with HRD1 is HERP, the mammalin homologue of the 
yeast protein Usa1p. It contains a cytoplasmic ubiquitin like domain and is required 
for the degradation of some substrates 177. 
HERP is recruited to the dislocation machinery by its binding to the putative 
dislocation channel Derlin-1 and although its activity seems to be dispensable for 
glycoprotein breakdown, it seems to be essential for breakdown of non-
glycosylated proteins 178. 
 
The mammalian homologue of yeast Hrd1p interacting protein, Hrd3p, was 
identified with the protein SEL1L, which interacts with mammalian HRD1 and 
allows the recognition of misfolded substrates that, subsequently, come in contact 
with the ubiquitin ligase HRD1. SEL1L is a component of an ER multiprotein 
complex implicated in the recognition and dislocation of misfolded proteins 98,179.  
SEL1L is a type I transmembrane glycoprotein with five N-linked glycans; the bulk 
of the protein composed of eleven copies of the short tricopeptide-like Sel1 
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repeats exposed to the ER lumen 179,180 and a type II fibronectin domain present at 
the N-terminus of its large luminal part 181. This domain is a small compact two-
disulphide-bond module, which is missing in SEL1L invertebrate homologues 
suggesting the acquisition of an ulterior function in higher organisms. 
The central portion of the protein is divided in three large clusters of Sel-1 like 
repeats, a subtype of the tetratricopeptide repeat (TPR) from residues 183 to 326, 
373 to 554 and from 627 to 699 residues. TPRs are present in multiple copies in 
several proteins and are modules for protein protein interaction.  
These domains consist of degenerate 34 aminoacids repeats oftenly organized in 
tandems with conserved aminoacid residues, hydrophobicity and spacing patterns. 
In particular a TPR is arranged in antiparallel amphipatic α-helices that help 
proteins interaction and multiprotein complexes assembly. These repeats seem to 
bind transcriptional regulators and component of signal transduction cascade 182. 
The fibronectin domain probably can bind to chaperones or directly to misfolded 
proteins; alternatively it can recruit substrate recognition proteins such as EDEM 
or OS-9 the mammalian homologue of the yeast Yos9. 
The Hrd3-like motif originally discovered in yeast Hrd3p consists of twelve 
aminoacids residues from 664 to 675 and is important for the interaction with the 
ubiquitin ligase HRD1. 
The proline rich motif is located at the C-terminus of SEL1L (from 770 to 793 







Figure 9: Organisation of SEL1L domains. SEL1L contains a signal sequence for its insertion in the 
ER lumen, a fibronectin type II domain, three clusters of SEL1-like repeats, an Hrd3p-like motif, a 
transmembrane domain that anchors the protein to the ER membrane and a proline rich tail. 
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SEL1L has a short half-life of about 180 minutes and its degradation seems to be 
proteasome dependent. Moreover, SEL1L remains completely susceptible to 
Endoglycosidase H treatment, suggesting that it resides exclusively in the ER 
compartment and does not traffic through the Golgi and secretory pathway 98. 
SEL1-L interacts with the transmembrane ERAD component HRD1 and with the 
ATPase VCP/p97. It also interacts with Derlin-1 and Derlin-2, two multispanning 
membrane proteins that seem to have a role during ER-to-cytosol dislocation of 
proteins 139,179. 
These interactions are abolished when the C-terminal portion of SEL1L, containing 
seven luminal SEL1 repeats, the transmembrane and cytosolic regions, are 
deleted (SEL1L1-372); this suggests the requirement of an intact luminal portion of 
SEL1L for the formation of the complex 183. 
During UPR the expression of HRD1 is induced by IRE-XBP1 pathway whereas 
expression of SEL1L is induced by ATF6 184. 
SEL1L is also associated with cell fate determination, cell differentiation, cell 
transformation and cancer progression 181. 
Two ER-resident lectins OS-9 and XTP3-B were found to bind to SEL1L and the 
binding requires a domain that shows a conserved mannose 6-phosphate 
homology (MRH), which doesn’t interact with the substrate. 
OS-9 and XTP3-B bind to glycans of proteins and probably recognise ERAD 
substrates by the presence of a lower mannose structure deriving from α-
mannosidase and EDEM demannosylation 183. 
SEL1L coprecipitation with XTP3-B, OS-9 and HRD1 ubiquitin ligase suggested 
that in mammalian cells the homologue of the yeast complex Hrd1p-Hrd3p-Yos9 is 
conserved. 
This complex would form a scaffold for ERAD of both glycosylated proteins and 
non-glycosylated misfolded proteins 185.  
SEL1L and HRD1 are involved in degradation of many substrates: among them 
unassembled µs chains are well-defined substrates of ERAD whose degradation 
has been described to depend on both SEL1L and HRD1 expression 186. 
Recruitment of proteins to HRD1 occurs either directly or indirectly through 
transient association of SEL1L with OS-9, XTP3-B, EDEM1, BiP or GRP94 a 
member of the Hsp90 family 60,183. 
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Others SEL1L interactors are PDI and calnexin and two proteins UBXD8 and 
UBXD2 that seem to be associated with the dislocation machinery and likely 
involved in recruitment of p97 to the dislocation complex 187. 
It has recently been suggested different requirements for ERAD of soluble or 
membrane proteins that bare defects in the luminal domain (ERAD-L), by using 
the same ERAD substrate in two different versions: membrane tethered and 
soluble. The finding was that only soluble substrates of ERAD-L strictly require the 
participation of proteins of the HRD1 pathway. ERAD of soluble substrates, named 
ERAD-LS, depends on the activity of the HRD1 ubiquitin ligase, SEL1L and the ER 
lectins OS-9 and XTP3-B. In contrast ERAD of membrane tethered proteins, that 
carry defects in luminal domains, seems to not be affected by inactivation of those 
HRD1 pathway proteins and is named ERAD-LM 188. 
Participation of OS-9 and XTP3-B is dispensable when proteins are membrane 
anchored thus, in contrast to yeast, demannosylation in mammals is not only 
linked to the binding to lectins. So up to now the need to unravel how ERAD 
membrane proteins are selected for degradation persists. 
OS-9 and XTP3-B seem to be interchangeable during shuttling of soluble 
misfolded proteins to the dislocon and in this work it is hypothesised that 
membrane tethered proteins can laterally diffuse within the ER membrane and 
reach the dislocon. 
 
Both SEL1L and HRD1 belong to the family of unfolded protein response genes 
that are induced during ER stress due to the accumulation of misfolded proteins 
189. 
Induction of SEL1L and HRD1 encoding genes ensure a more efficient recognition 
of misfolded substrate and degradation. 
 
Recently it has been discovered the existence of other two splicing isoforms of 
SEL1L: with SEL1L-A it is indicated the transmembrane glycoprotein resident in 
the ER while the other two are secreted isoforms (SEL1L-B and –C) both lacking 
the SEL1L membrane –spanning region. SEL1L-B retains the SEL-1-like repeats 
and is able to participate in the formation of multi-protein complexes while SEL1L-
C that lacks the repeats does not maintain this ability, suggesting that SEL-1 like 
Introduction  
 35 
repeats are functionally responsible of multi-protein complex formation and signal 
transduction 190. 
Peroxisomal localisation of SEL1L-C suggested a role in peroxisomal quality 
control that targets protein for degradation through an ubiquitinylation pathway 
similar to ERAD 191. 
Beside the role in protein degradation SEL1L is a crucial participant in cell cycle 
regulation, tumour progression and tumour invasiveness through modulation of 
genes related to cell-matrix interactions 192. In addition a series of human primary 
breast carcinomas show reduced levels or complete absence of SEL1L 193. Both in 
breast cancer and human pancreatic carcinomas SEL1L levels affect expression 





Figure 10: HRD1/SEL1L complex during ERAD pathway. SEL1L, OS-9 and XTP-3B cooperate in 
substrate recognition. After recognition the substrate can start to dislocate from ER lumen to the 
cytosol, probably crossing the lipid bilayer through a channel, or by ER extraction within lipid 
droplets. Retro-translocation requires ATP hydrolysis carried out by the p97 ATPase, which 
probably drives the dislocation process, or allows the substrate, already dislocated, to be released 
in the cytosol. 
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1.5.3 Retro-translocation machinery 
 
Membrane and secreted proteins must be retro-translocated into the cytosol to be 
degraded by the proteasome. 
There are basically two theories about how protein retro-translocation into the 
cytosol can occur: the first hypothesis bases the retro-translocation process on the 
activity of a channel called retro-translocon whereas the second one is the lipid 




1.5.3.1 The retro-translocation channel 
 
Regarding the first hypothesis there are evidences of the involvement of Sec61 in 
the retro-translocation process. Sec61 constitutes a proteinaceous pore for the 
delivery in the ER of secreted, ER resident, or membrane anchored proteins.  
Subunits of Sec61 were found to bind various ERAD substrates during 
degradation. MHC class I molecules have been found to bind Sec61 before their 
delivery to the proteasome when coexpressed with two small transmembrane 
proteins of human cytomegalovirus (HCMV) termed US2 and US11 
immunoevasins that down-regulate MHC-I expression with the aim of escape the 
immune system 194. Moreover, Cholera toxin once endocytosed within the cell and 
transported to the ER needs to be retro-translocated to the cytosol through its 
binding to Sec61 138. 
One hypothesis is that the differential binding partners induces modifications of the 
Sec61 channel in order to function in the opposite ways of translocation into the 
ER and retro-translocation into the cytosol 195. 
However the involvement of Sec61 in retro-translocation process remains 
controversial and still under investigation. In some cases it has been demonstrated 
the exit of proteins from the ER fully glycosylated; this suggests that the channel 
involved in retro-translocation should be larger than the import channel that has to 




In addition the yeast Der1p and the family of Derlin proteins in mammals have 
been described as candidates for being putative retro-translocation channels. The 
yeast Derp is a component of the Hrd1 ERAD-L complex through its interaction to 
Usa1. 
Yeast Der1p is predicted to span the ER membrane four times with both N-
terminus and C-terminus facing the cytosol 140. In yeast it was proposed that the 
retro-translocation channel for misfolded luminal domains consists of Hrd1 
ubiquitin ligase complex, Der1p and Usa1p. Usa1p would be the mediator for the 
association between Hrd1p and Der1p in order to link together ubiquitinylation and 
retro-translocation 147. 
 
Derlin-1 is the mammalian homologue of the yeast Der1p that shares the same 
topology 98,139 and is probably implicated in retro-translocation 140,197. 
There are evidences that Derlin-1 binds to misfolded and ubiquitinylated proteins. 
Down-regulation by RNA interference of Derlin-1 of C. Elegans provokes ER 
stress, supporting the hypothesis of its essential activity during ERAD process 98. 
Supporting this evidence experiments of RNA interference of Derlin-1 have been 
performed showing a marked increase of CFTRΔF508 198. 
Other evidences supporting the view of Derlin-1 as a key component of retro-
translocation channels come from experiments in which MHC class I molecules 
are retro-translocated into the cytosol of HCMV infected cells by the interaction 
with the p97 ATPase and Derlin-1. In particular Derlin-1 is able to bind prevalently 
glycosylated but also deglycosylated MHC class I molecules 98,139. Moreover, it 
associates with peptide-N-glycanase at the ER membrane, suggesting the 
possible role in recruiting cytosolic deglycosylating enzymes, consistently with its 
interaction with both MHC class I molecules glycosylated and deglycosylated 199. 
More recent studies showed that Derlin-1 interacts with the ATPase p97 and 
through this binding it can associate with the ubiquitin ligases HRD1 and gp78 
179,200. 
Derlin-1 has been associated with the retro-translocation of Cholera toxin although 
it is not excluded its transport to the cytosol through Sec61p channel. The 




Further evidences that Derlin-1 could be involved in retro-translocation came from 
an in vitro retro-translocation approach. In this study retro-translocation of 
fluorescent pro-alpha factor from ER microsomes was measured as decrease in 
fluorescence due to the presence in the cytosolic fraction of a quenching agent. 
Antibody against Derlin-1 blocked the decrease in fluorescence while antibody 
against Sec61 allowed a decrease in fluorescence to occur due to capability of 
pro-alpha factor to retro-translocate and loose its fluorescence by the activity of 
the quenching agent 202. 
 
In mammals there are other two Der1p-homologues, Derlin-2 and Derlin-3 that 
similarly to Derlin-1 contain four hydrophobic domains with both N-terminus and C-
terminus facing the cytosol 203. 
Derlin-2 and 3 demonstrated also to be required for degradation of misfolded 
glycoproteins; they associate with the substrate, p97 and EDEM.  
Derlin-2 helps the formation of p97-EDEM complex mediating the association of 
p97 with the substrate. 
 
To complicate a poorly understood scenario there is the discovery of another 
protein, TRAM1, probably involved in disposal of ER degradation substrates. 
TRAM1 was previously characterised for its function during translocation of 
nascent polypeptides in the ER 204. 
Lack of TRAM1 limits the extraction of proteins from the ER and leads to an 
increased UPR 205. In this work it is also demonstrated that the role of TRAM1 is 
important for the disposal of membrane substrates independently of their 
glycosylation status but it doesn’t act on soluble substrates. 
 
More recently BAP31, a three membrane spanning ER protein, previously 
demonstrated to be involved in protein sorting 206, has been described to be 
possibly implicated in retro-translocation process. In fact, BAP31 has been found 
to interact with the Sec61 translocon and with a factor acting during the insertion 
into ER membrane of membrane anchored protein, TRAM 207. 




BAP31 knock down experiments have shown an increase in the amount of 
CFTRΔF508 but the fraction of CFTRΔF508 coimmunoprecipitated with Derlin-1 
was lower. This result suggested that Bap31 has an important role in promoting 
the interaction of Derlin-1 with the substrate 207. 
 
In yeast another putative retro-translocation channel, build up by Hrd1p 
oligomerisation following Usa1p activity, has been proposed. In particular the 
multiplication of transmembrane segments of Hrd1p has been demonstrated to be 
required for protein degradation probably due to its activity in dislocation of 
proteins from ER to cytosol 208,209. 
 
1.5.3.2. Lipid droplets in ER to cytosol dislocation 
 
Lipid droplets are organelles for the storage of lipids in mammalian cells that can 
form soon after an increase in fatty acids levels 210; they bud from the ER 
surrounded by a single layer of phospholipids and are believed to be formed by 
lipid ester deposition between the two leaflets of ER membrane 211,212. 
Protein composition of lipid droplets differs form the ER protein content due to the 
presence of proteins such as adipophilins and perilipin, that are specifically 
inserted in lipid droplets 213. Recognition of these lipid droplets specific proteins 
could help in the identification of these structures.  
A possible involvement of lipid droplets in the escape of proteins from the ER in 
order to allow their proteasome-dependent degradation has been recently 
proposed for type I membrane proteins. The protein taken into consideration was 
the MHC class I molecule targeted for retro-translocation and degradation by the 
two immunoevasins of the human cytomegalovirus, US2 and US11 194. These 
proteins are expressed by HCMV in order to avoid the recognition by the immune 
system of viral peptides loaded on MHC-I molecules of infected cells. 
The hypothesis is that MHC-I molecules can be discarded from the ER either as 
part of lipid droplets or as a structure composed solely of MHCI molecules and 
phospholipids. US2 and US11 are supposed to be able to create a suitable 
environment for the formation of bicellar structures through the recruitment of 
proteins that could promote lipid rearrangements 141. To support this hypothesis 
there are works on apoliprotein B (ApoB) in which it has been demonstrated that in 
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cells that actively degrade ApoB there is an association between lipid droplets and 
ApoB, ApoB is ubiquitinylated and recruits the proteasome 214. 
 
1.5.4 ATP dependent extraction of ER proteins to the cytosol 
 
In order to reach the cytosol, proteins with a degradative fate must follow a series 
of steps that are still a matter of intensive study. 
What is already known is that after retro-translocation proteins that are substrates 
for degradation are recognised by a series of ubiquitin binding proteins that escort 
proteins from the ER membrane to the proteasome 215,216. 
An essential protein involved in these steps is, in yeast, the ATPase cdc48 and in 
mammals ATPase p97.  
The p97 and cdc48 couple ATP hydrolysis with different cellular activities, among 
which there is the activity in releasing proteins with degradative fate from the ER 
217. The p97 consists of six subunits each containing two ATPase domains (D1 
and D2) that are arranged in a homo-hexameric ring configuration. The bottom of 
the hexameric ring forms a central pore that seems to accommodate the protein 
targeted for degradation 218; this hexameric structure seems to undergo large 
dynamic conformational changes during ATP hydrolysis that are likely linked to the 
process of unfolding of the protein 219,220. 
The p97 and cdc48 are abundant in the cytosol and in the nucleus but a 
considerable fraction is tightly associated to the ER membrane on the cytosolic 
side 142,221. 
The cdc48 seems to be recruited to the membrane through UBX-domain-
containing membrane protein Ubx2 149,222, while in mammals p97 can be 
associated to the membrane by the interaction with the valosin-containing protein 
VIMP 98. 
Beyond their pivotal role in ubiquitin-dependent degradation 223 these ATPases are 
involved in many cellular processes such as apoptosis, post-mitotic membrane 
fusion of ER and Golgi membranes, spindle assembly after mitosis, nucleic acid 
repair and replication 224,225.  
They can bind to different partners and the ability to form different complexes 
seems to determine their different functions. 
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In yeast cdc48 has two associated factors, Ufd1 and Npl4, which contain poly-
ubiquitin binding domains. These two cofactors are conserved in mammals and 
are called UFD1 and NPL4. The binding of the ATPase with these two proteins 
directs the activity towards ER degradation 226. 
The complex cdc48-Ufd1-Npl4 has been described to be implicated in the release 
of polypeptides from the ER membrane 227. 
Also p97 has been associated with protein extraction from the ER 223 and also in 
mammals there are evidences that for this activity it requires the binding to two 
cofactors present in a heterodimeric complex: UFD1 and NPL4 223,228. 
The UFD1 and NPL4 bind ubiquitinylated substrates through ubiquitin binding 
domains whereas previous studies indicate that p97 transiently associates with 
proteasome. This suggests a role of p97 in facilitating the interaction between 
ubiquitinylated proteins associated with NFD1 and NPL4 and the proteasome 
229,230. 
Noteworthy, is the finding that p97 is always detected in association with SEL1L 
and Derlin-1 179. 
The ATPase activity of p97 can act on retro-translocation by providing the energy 
for dislocation or allowing the release of substrates that have been already retro-
translocated 136. 
A recent work has collected a number of observations that suggest the function of 
p97 as unfoldase. The p97 would lead the substrate to acquire a poorly folded 
state that would allow proteasomal degradation 231. 
Regarding p97 interaction with substrates an endogenous inhibitor of ERAD has 
recently been characterised and named SVIP (small p97/VCP interacting protein) 
232. 
SVIP was previously described to be localised in the cytosol and to be anchored to 
the ER membrane through myristoylation. In this work it was described that SVIP 
overexpression causes cellular vacuolation due to the dilatation of ER 233 and 
more recently it has been described to form a complex with Derlin-1 and p97 232. 
In particular it was postulated that SVIP reduces the association of ERAD 
substrates with the gp78 ubiquitin ligase and p97, avoiding protein ubiquitinylation 
and degradation 232. These findings confirm either the essential role of p97 during 




1.5.5 Deglycosylation and ubiquitin escort factors 
 
The link between proteasome machinery and degradation of substrates retro-
translocated to the cytosol seems to be determined by deubiquitinylating enzymes, 
deglycosylating enzymes and ubiquitin binding factors 216. 
Peptide N-glycanase (PNGase) a deglycosylating enzyme has been proposed as 
a possible candidate for protein-proteasome connection. PNGase was discovered 
in yeast and is responsible for the deglycosylation of N-linked glycoproteins. 
Despite of its broad range of substrates it acts only on misfolded glycoproteins that 
have been dislocated from the ER to the cytosol 234,235. 
Analysing possible interactions Rad23 protein was identified as a PNGase 
interactor 236. 
There are evidences that the 26S proteasome is bound to a fraction of Rad23 
(Rad23p) through its N-terminus ubiquitin like domain 237. Therefore, it is possible 
that PNGase interacts with the proteasome through its interactor Rad23, 
suggesting an involvement of PNGase in the ERAD process 238,239. 
Rad23 is part of a class of ubiquitin-like domain (UBL) proteins that include also 
Dsk2. UBL domain confers to these proteins the ability to bind 26S proteasome 
237. 
Besides their UBL domain Rad23 and Dsk2 contain an ubiquitin associated 
domain (UBA), which is a sequence of about 45 aminoacid residues specific for 
ubiquitin chains 240. Due to the presence of UBL and UBA domains that recognise 
polyubiquitinylated proteins Rad23 and Dsk2 have been proposed as shuttling 
factors able to target ubiquitinylated substrates toward the proteasome by binding 
simultaneously both the proteasome (through UBL domain) and the substrate 
(through UBA domain) and for this reason they are collectively named ubiquitin 
receptors 132,241,242. 
Rpn1 and Rpn10 subunits of the proteasome are able to interact with UBA-UBL 








2. HCMV dependent dislocation/degradation of MHC class I molecules 
 
2.1 MHC class I structure and function 
 
MHC class I molecules are glycoprotein expressed on the cell surface involved in 
immunodetection and elimination of virally infected cells or transformed cells.  
They can bind a broad array of peptides that are generated intracellularly, in order 
to present them at cell surface to cytotoxic T cells 243. 
Dendritic cells, which are very potent antigen presenting cells (APC), are also able 
to present on MHC-I peptides that derive from exogenous antigen in a peculiar 
pathway called “cross-presentation” 244. 
An MHC class I molecule contains a large α chain associated non-covalently with 
a β2 microglobulin. The α chain is a type I transmembrane glycoprotein of about 
45 kDa and is encoded by genes in A, B and C regions of the human HLA 
complex and contains hydrophobic transmembrane segment and hydrophilic 
cytoplasmic tail. 
The β2 microglobulin is an invariant protein with a weight of about 12 kDa. 
Association between α chain and β2 microglobulin is essential for the membrane 
expression of MHC-I molecules. 
Both α chain and β2 microglobulin are synthesised by polysomes in the ER. MHC-
I assembly involves the activity of ER resident chaperones, in particular calnexin. 
Moreover, for the stability of class I molecules the binding to an 8-9 aminoacids 
long peptide is required 245,246. 
Cell specialysed in the recognition of peptides loaded on MHC-I molecules are the 
Cytotoxic T lymphocytes (CTLs). CTLs are CD8+ cells restricted to the recognition 
of peptides presented by MHC-I molecules by the cell surface receptor termed 
TCR. Since every kind of nucleated cell expresses MHC-I, CTLs can recognise all 
types of transformed or infected cell. 
CTLs immune response takes place through two different steps: the first phase 
serves to activate and differentiate naive TC cells into functional CTLs. 
Upon interaction of TCR expressed on TC cell with peptide presented on MHC-I 
molecules by antigen presenting cell, in particular dendritic cells (DCs), TC cells 
start to proliferate and differentiate into CTLs. 
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The second phase involves the recognition by antigen activated CTLs of MHC-I 
molecules complexed with a specific peptide on target cells. Following recognition 
CTLs initiate the effector phase that leads, by the secretion of lytic granules to the 
killing of the target cell. 
CTLs immune response is directed to allogenic cells, transformed cells, virus 
infected cells and chemically conjugated cells. The capability of CTLs to recognise 
and destroy viral infected cells forced different viruses to develop strategies to 
evade the immune system. Several viruses have been found to produce proteins 
interfering with specific or non-specific host defences. For instance a viral defence 
against non-specific host defence is represented by the capability to overcome 
interferon α and β activities, which are expressed by the cell in response to viral 
infection. Other viruses continuously mutate their proteins in order to avoid 
recognition while other viruses interfere with the immune response suppressing 
peptide presentation by MHC-I molecules 247. 
 
 
Figure 11: Structure of MHC class I molecule constituted by the α chain with three domains (α1, α2 
and α3) and β2 microglobulin. The α chain creates a groove for the binding to peptides. 
 
2.1.1 Folding of MHC-I molecules  
 
During translation MHC-Iα binds rapidly the transmembrane chaperone calnexin 
and the associated ERp57, a member of protein disulphide isomerase (PDI), 
which enables the formation of proper disulphide bonds in glycoproteins that have 
been just inserted into the ER membrane 248,249. Association with calnexin ensures 
inhibition of α chain degradation and allows the formation of disulphide bonds in 
the α2 and α3 domains by ERp57. 
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Afterwards MHC-Iα chain associates with β2 microglobulin in a highly unstable 
heterodimer which is stabilised by calreticulin that replaces calnexin 245,246,250. 
This binding cause the change in MHC-Iα conformation which is now able to bind 
peptides and to enter the peptide loading complex (PLC) whose components are: 
MHC-Iα-β2 microglobulin heterodimer, calreticulin, ERp57, tapasin, the transporter 
associated with antigen processing (TAP) and Bap31.  
Tapasin plays an important role during MHC-Iα folding acting as a bridge between 
TAP and the other components of the PLC. Tapasin allows the stabilisation of 
either TAP or the entire PLC 251,252 and is linked to ERp57 through a disulphide 
bond 253. 
Peptides presented on MHC class I are produced mainly in the cytosol and can 
come from various sources including endogenous or viral cytosolic proteins, 
proteins retro-translocated to the cytosol from the ER or proteins internalised. 
All of these proteins generate peptides following proteasomal degradation that are 
then transported into the ER by the transporter associated with antigen processing 
(TAP). Peptides that match with the binding groove of MHC-I are loaded on class I 
molecules with the assistance of the PLC.  
However, peptides trasported through TAP are frequently longer than the 8-10 
residues length suitable for MHC-I loading and therefore, the activity of ER 
associated peptidases is required. In humans there are two ER aminopeptidases 
named ERAP1 254,255 and ERAP2 256 that seem to complement their function; 
ERAP1 cleaves peptides with hydrophobic residues whereas ERAP2 cleaves 
peptide with basic residues 256,257. 
Thanks to the physically association to TAP, MHC-Iα-β2 microglobulin complex 
can easily associate with peptides. 
Following peptide association MHC-I acquires more stability, dissociates from 
calreticulin and TAP and its vesicular export from the ER can start through a 
process that involves Bap31 and possibly other export receptors 258. 
 
 
2.2 HCMV immunevasion: affecting MHC class I-peptide complex recognition 
 
Human cytomegalovirus (HCMV) can cause serious diseases in 
immunosuppressed or immunodeficient patients and in children; it infects many 
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cell types including epithelial, glial fibroblast endothelial cells and 
monocytes/macrophages. HCMV replicate slowly in most cells and it establishes a 
latent state in monocyte/macrophages: its life cycle is actually characterised by 
periodic reactivation and replication. HCMV can survive thanks to its ability to 
compromise the immunological mechanisms that ensure the recognition of 
infected cells by T lymphocytes and natural killer cells 259,260. 
The ability to inhibit this recognition is characteristic of many viruses that encode 
proteins that affect cell surface expression of MHC-Iα: down-regulation of MHC-Iα 
molecules is a mechanism that the virus uses to escape the cellular immune 
response and is known as immunoevasion 261. 
In particular HCMV contains in its genome a unique short region S (US) that 
encodes for eight membrane glycoproteins involved in immunoevasion and thus 
called immunoevasins 262. 
These proteins are differentially expressed during the viral life cycle and with 
different ways of action they affect cell surface expression of MHC-Iα. Among 
these proteins, US3 is the earliest expressed after infection and prevents 
trafficking of newly synthesised MHC-Iα molecules causing their retention in the 
ER compartment 263. Afterwards two proteins that induce specific proteasomal 
degradation of MHC-Iα are expressed: these proteins called US2 and US11 are 
independently sufficient for the dislocation of MHC-Iα molecules newly 
synthesised in the ER 235,262. 
MHC-Iα molecules upon interaction with US2 and US11 start the dislocation to the 
cytosol and, as soon as the exposition to the cytosolic face has occured, the 
enzyme N-glycanase removes the N-glycan from its sequence allowing the protein 
to entry into the proteasome 264-266. 
MHC-Iα molecules degradation pathway induced by US2 and US11 follows a 
series of steps very similar to the ERAD of misfolded proteins 136,264. 
A protein that works both at early and late times post-infection is US6, that blocks 







2.2.1 US2 and US11 activity 
 
US11 is a type I transmembrane glycoprotein with an N-terminal ER luminal 
portion, a transmembrane domain and a short cytoplasmic tail. 
The specificity of US11 activity is directed to α1 and α2 luminal domains of only 
some MHC-I molecules. Depending on the aminoacid composition of these two 
domains US11 association and affinity with MHC-Iα can be different. In fact, US11 
causes downregulation of MHC-I molecules, in particular it is specific for HLA-A2 
and for members of the region C (HLA-C) 268,269. 
Further elucidations on how US11 mediates MHC-Iα retro-translocation and 
degradation come from the findings that US11 seems to work independently of the 
tertiary structure of MHC-I molecules, thus working both on folded or misfolded 
molecules and it catalyses the polyubiquitinylation of MHC-I 270,271. 
The US11 pathway exploits the activity of the ERAD proteins Derlin-1 and SEL1L. 
SEL1L is involved in the retro-translocation of MHC-I molecules and is essential 
for US11 mediated MHC-I molecules dislocation into the cytosol 98,180. 
The proposed model is that US11 has the specific function of delivering MHC-Iα 
molecules to HRD1/SEL1L complex, promoting their rapid dislocation and 
degradation 187. 
US11 transmembrane domain is essential for its ability to induce retro-
translocation of MHC-Iα molecules, it contains a glutamic residue which could 
interact with host proteins; this suggestion is supported by the finding that a US11 
mutant in which glutamic residue 192 is mutated to leucine (US11Q192L) is no 
more able to induce dislocation of MHC molecules because Derlin-1 binding site is 
disrupted 271. 
Noteworthy, once expressed in the cell, US11 induces the UPR response 
activating XBP-1 splicing, while the US11Q192L does not. 
This indicates that UPR is not induced merely by US11 expression, but is 
dependent on the interaction between US11 and Derlin-1 within the ER lipid 
bilayer 272. 
 
US2 shares the same topology of US11 and, in spite of the presence in the 
sequence of a site of N-glycosylation, US2 can be found both in glycosylated and 
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non-glycosylated form. The non-glycosylated form is supposed to derive from an 
inefficient insertion in the ER, caused by the presence of a non-cleavable signal 
peptide, which could diminish the efficiency of ER insertion. Inefficient insertion 
would therefore lead a fraction of protein to be localised in the cytosol in a non-
glycosylated form 273. 
US2 recognises MHC-Iα molecules through an immunoglobulin–like fold, which 
targets the luminal part of MHC-Iα soon after synthesis. Following interaction with 
US2, MHC-Iα molecules are transported back to the cytosol, where steps of 
deglycosylation and proteasome-dependent degradation take place 270. 
US2 interacts with HLA α2 and α3 regions and is able to down modulate HLA-A2, 
HLA-B27 and HLA-G 269. 
Compared to US11 activity, the US2 pathway is less understood, but it seems to 
be dependent on the activity of signal peptide peptidase, a protease that cleaves 
polypeptide within the membrane 274. Furthermore it has been demonstrated the 
critical requirement of a functional ubiquitin system 275 and very recently it has 
been characterised the TRC8 E3 ligase acting in the US2 pathway 276. 
Differently from US11, US2 seems to display its activity preferentially on properly 
folded MHC-Iα molecules, which upon US2 contact and dislocation are modified 
with 3-5 ubiquitins 271. 
In order to promote MHC-Iα molecules dislocation, US2 needs its cytoplasmic tail, 
where some important residues reside: cysteine 187, serine 190, tryptophan 193 
and phenylalanine 196 are likely involved in the interaction with the retro-
translocation machinery. Upon tight interaction between US2 and MHC-Iα has 
occured, the cytoplasmic tail of US2 would engage the retro-translocation 
machinery 277. 
To further confirm these suggestions the cytoplasmic tail of US2 was fused to 








Figure 12: Illustration of US2 and US11 degradative activity against MHC-Iα molecules. Once 
engaged by US2 and US11, MHC-Iα molecules start to dislocate from the lumen of ER to the 
cytosol, probably crossing the lipid bilayer through a channel. After retro-translocation MHC-Iα 
molecules are subjected to a deglycosylation step by enzymes localised in the cytosol and finally 







Antibodies or immunoglobulins are glycoproteins expressed by B lymphocytes, as 
membrane bound or secreted molecules; antibodies are the central effectors of the 
humoral immune response due to their ability in recognising and binding foreign 
molecules with high specificity 279. 
All antibodies are made up of four polypeptide chains; two light chains of 23 kDa 
and two heavy chains of 50 to 75 kDa. Every light chain is bound to a heavy chain 
by an interchain disulphide bond and by a combination of ionic bonds, hydrogen 
bonds and hydrophobic interactions. 
Similar interactions are responsible for the binding of the two identical heavy 
chains. 
A peculiar characteristic of immunoglobulins is the presence of homologous 
repeated sequences either in the heavy chain and in the light chain; these 
domains are about 110 aminoacids long that give rise, once folded, to a compact 
globular structure. These immunoglobulin domains are formed by two series of β 
sheets with antiparallel orientation. The resulting immunoglobulin domain is 
stabilised by hydrophobic interactions and by conserved disulphide bonds that link 
together the two series of β sheets 280. 
Both heavy and light chains contain constant and variable regions; variable 
regions are responsible for antigen binding, while constant regions are responsible 
for effector functions. 
There are five different isotypes in the constant region of heavy chain that 
generate five classes of antibodies: IgA, IgE, IgG, IgD and IgM. Depending on 
which type of constant region the antibody contains, different effector functions 
can be carried out.  
IgA, IgD and IgG contain three constant domains and a hinge region whereas IgM 
and IgE contain four constant domains and no hinge region 281. 
IgG: is the most represented class of immunoglobulins, made up by two γ heavy 
chains. IgGs can activate the complement and bind with high affinity the FC 
receptors expressed on phagocyte membrane mediating the opsonization. 
IgM: are expressed as monomers on B cell surface or are secreted by plasmacells 
as pentamers or hexamers 282. 
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IgA: are the predominant immunoglobulins at the level of external secretion such 
as oral surface where they can be found as dimers or trimers 283. 
IgD: are present in the serum at very low levels, but together with IgM are the main 
immunoglobulins expressed on the surface of mature B lymphocytes 282. 
IgE: is the less abundant immunoglubulin class in the serum, they are involved in 
allergies and in particular they mediate sudden hypersensitive reactions that give 
raise to asthma, orticaria and anaphylactic shock 281. 
 
 
3.1 IgE-FcεRI interaction: effector mechanisms 
 
IgE immunoglobulins are able to induce a strong immune response involved in 
allergic reactions and immunity against parasites; recent studies also suggested 
an important role of IgE in cancer immune-surveillance 284,285. 
IgE heavy chains contain four constant domains responsible for effector functions 
(εCH1, εCH2, εCH3 and εCH4) displaying six N-linked glycosylation sites and one 
variable domain (VH) 286. 
In order to exert the effector functions IgE must bind to the high affinity IgE 
receptor (FCεRI) mainly expressed in mastcells. For binding to the receptor the 
IgE εCH3 region is essential 287. 
IgE high affinity receptor is a membrane glycoprotein that plays a fundamental role 
in hypersensitive reactions mediated by IgE. In humans it exists in two different 
forms: one tetrameric and the other one trimeric 288. 
The first one is constituted by a tetrameric complex that comprises one α subunit, 
one β subunit and a γ subunit homodimer (αβγ2) and is expressed on IgE 
associated effector cells, mastcells and basophils. The second form is constituted 
by a trimeric complex (αγ2) which lacks the β subunit and is expressed on 
Langerhans cells 289,290, monocytes, eosinophils 291, peripherical dendritic cells 292 
and platelets 293 and is involved in the internalisation of IgE/Antigen complexes. 
The β chain is known to act as an amplifier of IgE-mediated functions and seems 
to enhance expression of FcεRI molecules 294,295. 
Subunit α is responsible of binding to IgE; in particular the CH3 domain of IgE is 
recognised by FCεRI-α chain. The α subunit is in turn constituted by two 
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extracellular immunoglobular domains (D1 and D2): the D2 domain is the main 
responsible of IgE interaction and the D1 domain seems to have structural 
relevance in the maintaining of high affinity for IgE and a correct folding of D2 
domain 296,297. 
The α subunit is highly glycosylated because it contains seven sites of 
glycosylation 298. The β subunit is essential for α subunit expression on the cell 
surface and, together with β subunits, for the regulation of several genes 
transcription and for signal transduction cascade that ends up with secretion of 
mediators and the synthesis of proinflammatory metabolites. 
The two γ subunits form a heterodimer through disulfide bonds and in the γ subunit 
cytosolic tails conserved motifs, known as ITAM, are located. ITAM motifs are able 
to interact with tyrosine-kinase proteins during signal transduction cascade. The 
binding of the antigen with the complex IgE-FcεRI, causes aggregation of FcεRI 
molecules, a rapid phosphorylation of tyrosine residues and degranulation of 
mastocytes 299. 
 
Figure 13: A) IgE structure characterised by the presence of four constant domains (Cε 1-4) B) 
Illustration of FcεRI constituted by one β chain, two γ chains and one α chain. FcεRI-α chain 
contains two domains: D1, responsible for IgE binding and D2 domain. IgE binds the receptor 









3.2 Antibodies as biotechnological tool 
 
Monoclonal antibodies derive from a single clone of B lymphocytes, they display a 
single VH-VL combination and are specific for a single epitope 300. 
Monoclonal antibodies (mAbs) have proved very useful not only as 
biotechnological tools (for example in antigen detection and purification), but also 
as therapeutic and diagnostic tools. 
However, since murine mAbs were responsible of several side effects, chimeric 
antibodies containing only the mouse-variable regions of the mAb and human 
constant regions have been produced showing reduced antigenicity 301. Another 
limitation in therapeutic usage of antibodies is represented by the immunoglobulins 
low capacity in penetrating poorly perfused tissues, including tumours; moreover 
the Fc fragment can influence the availability of the antibody to bind its antigen, 
because it can be captured by specific receptors on the membranes of monocytes, 
macrophages and natural killer cells. 
These limitations have favoured the design and production of small antibody 
derived molecules that maintain the specific binding to the antigen, but do not 
show the disadvantages of antibody molecules. 
 
Among all the different antibody fragments produced, the major breakthrough in 
this field is represented by the “single chain Fv” (scFv) antibody molecules. The 
scFvs are monovalent antibody molecules expressed as single polypeptide chain 
(single chain Fv) by the insertion of a flexible peptidic linker between the C-
terminus of a VH and the amino terminus of a VL (or vice versa) 302. The flexible 
linker ensures the correct interaction between VL and VH 303. 
Due to their small size, scFvs present a series of advantages over complete 
immunoglobulins, including a better penetrability into tissues and reduced toxicity 
304-306.  
In order to increase the avidity of scFv molecules another class of dimeric single 
chain antibody molecules has been developed: the small immunoproteins (SIPs). 
SIPs have been obtained by the addition to VL and VH domains of the CH3 
dimerizing domain from human IgG1 (γ1CH3), resulting in a bivalent scFv 307. SIPs 
overcome a series of limitations of scFvs: first SIPs maintain the bivalency of the 
original antibody, in addition, when administered to patients, their stability is higher 
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compared to scFv and, moreover, SIPs can penetrate tissues with the same 
efficiency, but with the advantage of having a slower clearance and therefore a 
longer permanence within tissues and tumours as well 308. 
Since many proteins are expressed intracellularly, the idea was to use mAbs 
directly in vivo to interact with the antigen and block its function.  
For this purpose, the production of antibody fragments allowed an easier selection 
of the antibodies able to fold properly also in the cytosol 309,310, giving the 
possibility to obtain a new class of antibodies named intrabodies 311. 
Intrabodies are any kind of antibody, including antibody fragments that remain 
confined within the cell 312. 
Intrabodies could be very useful to block protein-protein interactions, or protein-
nucleic acid interaction, to inhibit directly the function of an enzyme but also to 
redirect the target protein toward a different cellular compartment 313. 
As a matter of fact, intrabodies can be directed into different cellular compartments 
depending on the specific signal sequence used. 
Intrabodies can be directed into cytosol just through deletion of the leader peptide, 
to the nucleus through the use of NLS (nuclear localisation signal), to peroxisomes 
using SKL sequence for peroxisome retention or to the ER through the addition at 
the C-terminus of the protein of a KDEL sequence or other sequences described 






Figure 14: schematic representation of a complete IgG (A) scFv composed by VH and VL domains 
(B) and SIP that contains, in addition, the CH3 dimerizing domain which results in a divalent scFV 
(C). 
 
In this work we exploited the specificity of IgE for the FcεRI-α chain and the 
specificity of antibody molecules in scFv format (in particular scFv9E1) to induce 













4. TGEV spike protein S 
 
The porcine Transmissible gastroenteritis virus (TGEV) is a member of the 
Coronaviridae family of the Nidovirales order 315,316. It is an enveloped positive 
strand RNA virus that replicates both in enteric and respiratory tissues of newborn 
piglets, causing a mortality near to 100% 317. The TGEV structure is build up by 
four structural proteins: the spike glycoprotein S which conditions with its structure 
the enteric and respiratory tropism, the membrane protein (M) and the envelope 
protein (E), that are embedded in the virus envelope together with S protein and 
finally the nucleoprotein (N), that is bound to RNA + genome in the nucleocapsid. 
At the structural level, TGEV virus contains three different compartments: the 
envelope essential for virus infectivity, the internal core made up by the carboxy-
terminus of M protein and the nucleocapsid consisting of the RNA genome and the 
nucleoprotein N 318-320. 
The cellular receptor for TGEV infection is the porcine aminopeptidase N (pAPN), 
which is recognised by the viral protein S. S protein is a large type I 
transmembrane glycoprotein, which is also responsible for membrane fusion 321-
323. 
Against TGEV spike protein a mAb with neutralizing activity was produced and 
named 6A.C3 324. Oral administration into piglets of either mAb 6A.C3 or its 
derived SIP version has demonstrated to have a protective function against TGEV 
infection. 6A.C3 thanks to its neutralizing activity is able to inhibit TGEV 
In this work we have used the TGEV S protein as second model for the validation 
of our system to induce specific protein-knock out. In this case the specificity to act 













Image downloaded from http://expasy.org/viralzone/all_by_species/30.htm 
 
Figure 15: TGEV structure. 
The S protein is present in the envelope and is essential for virus infectivity, interaction with the 
host cell receptor. The M glycoprotein is essential for envelope formation whereas N protein 




































5 Protein biotinylation 
 
Beside the involvement of biotin in several metabolic pathways, biotin has a very 
interesting feature that resides in the high affinity for avidin, a glycoprotein present 
in eggs and for streptavidin, the avidin homologous produced in Streptomyces 
avidinii.  
Avidin and streptavidin can bind to biotin through a non-covalent interaction that is 
the strongest known, so far. Moreover (strept)avidin is a homotetramer in which 
every monomer can bind to biotin resulting in a tetravalent protein 326. 
Therefore, the strong binding between biotin and avidin could be exploited for a 
number of diagnostic and research purposes and for purifications of proteins. For 
these reasons, with the aim of mimic the physiological biotinylation of a system 
has been developed (in vivo biotinylation; 327). 
This system is based on the activity of E. coli enzyme BirA, which is the best biotin 
ligase characterised.  
BirA enzyme catalyses the biotinylation reaction through two ATP-dependent 
steps that allow the formation of a covalent linkage between the aminic group of a 
lysine residue, present within protein sequence, and the carboxylic group of biotin. 
During biotinylation reaction, ATP hydrolysis causes the formation of the 
intermediate biotinyl-AMP which is hydrolysed, in turn, in order to guarantee the 
transfer of biotin to lysine residue located within the BirA domain called biotin 
carboxyl carrier protein or BCCP 328. 
In order to identify the BirA consensus sequence a combinatorial study of protein 
biotinylated sequences was performed and a series of biotinylated peptides were 
found out 329. Analysis on N-terminal and C-terminal truncation variants of one of 
these peptides allowed the identification of a 14 aminoacid residues peptide able 
to mimic biotin acceptor domain of BirA; the sequence found GLNDIFEAQKIEWH 
was called Biotin Acceptor Peptide (BAP) 327. 
Since the BAP peptide constitutes an efficient target for the BirA enzyme, the 
addition of a BAP peptide in the sequence of heterologous proteins confers to 
those proteins the possibility to get biotinylated once in contact with BirA enzyme. 
Proteins bearing the BAP peptide and BirA can be coexpressed in mammalian 
cells in order to obtain biotinylated proteins in vivo (In vivo biotinylation). In vivo 
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biotinylation can be performed for secretory or membrane proteins through the 
expression of a BirA modified by the addition of a SEC leader peptide 330. 
In this work the in vivo biotinylation has been exploited for the study of molecules 
that, once committed for degradation, dislocate from the ER to the cytosol in the 
so called retro-translocation process. 
 
 
Figure 16: Biotinylation reaction steps. 
BirA enzyme catalyses the biotinylation reaction through two ATP-dependent steps; the first step 
catalyses the formation of the intermediate biotinyl-AMP, which is afterwards hydrolysed, in order 
















AIMs of the study 
 
The main objective of the present work was to exploit the ubiquitin-proteasome 
machinery to obtain specific degradation of defined proteins within the secretory 
pathway. 
Up to now, different strategies have been used to obtain intracellular specific 
protein inactivation: siRNA have been used to inhibit protein expression, while 
intrabody technology was used to inactivate proteins by inhibiting protein function 
or by promoting target protein relocalisation and subsequent inactivation. 
A great advantage of the use of intrabodies is given by the high specificity for the 
target. As a consequence of this high specificity, the possibility to have off target 
effects is extremely low. 
In order to bring together the possibility to inhibit target protein expression and to 
maintain the specificity conferred by antibodies, the idea was to create a fusion 
protein between a recognition moiety, represented by a scFv molecule or any kind 
of molecule able to specifically recognise the target such as a ligands, peptides, 
receptors or whatever antibody fragment and a moiety displaying a degradative 
activity. 
A candidate for being the degradative moiety was SEL1L, an ER transmembrane 
protein functioning during ERAD. SEL1L is involved in the recruitment of misfolded 
substrate in the lumen of ER, that after recognition are delivered to proteasome 
machinery for degradation. 
With the aim of specifically recognise proteins within the secretory pathway and in 
order to induce their degradation, we designed a new class of molecules termed 
degradins. Degradins result from the fusion of the COOH-terminal 372 aminoacids 
of human SEL1L with an antibody-derived scFv or a ligand of a receptor (scFv-
degradin or ligand-degradin). The COOH-terminal portion of the human SEL1L 
were previously demonstrated to be essential during ERAD 183. 
Degradins would therefore engage target proteins within the ER, promoting their 
dislocation to the cytosol and their proteasome-dependent degradation.  
 
ER-to-cytosol dislocation of aberrant proteins is a complex process poorly 




Up to now, there are just a few techniques that enable the detection of proteins 
that, once engaged within the ER lumen, are dislocated to the cytosol, where they 
are degraded by the proteasome.  
Those experiments are mainly focused on the study of very well known substrates 
of ERAD such as the MHC class I molecule. 
MHC-I molecules are targeted for dislocation and degradation by two viral proteins 
of Human cytomegalovirus named US2 and US11. 
So far, in order to detect retro-translocated MHC-I molecules most experiments 
were based on the separation of the cytosolic fraction or on the detection of 
deglycosylated molecules that accumulate in the cytosol, because retro-
translocated, upon proteasome inhibition 235,275. 
These techniques share the same weak points, they have a low efficiency due to 
the inability to detect retro-translocated molecules without the use of proteasome 
inhibitors and are not very specific. 
To overcome the limitations of these techniques and in order to enhance the 
specificity and the efficiency of retro-translocated molecules detection, we decided 
to exploit a compartmentalised reaction that can occur only on those molecules 
that have been dislocated to the cytosol where the enzyme displays its function. 
The reaction is the in vivo biotinylation carried out by the enzyme BirA 331. 
To assess whether biotinylation could be useful to study retro-translocation, we 
chose a membrane target protein already described to be substrate of the retro-
translocation process. This protein was the MHC-I α chain that we engineered 
through the addition of a BAP peptide at the N-terminus to be recognised by the 
BirA enzyme once dislocated to the cytosol. 
Membrane or secreted proteins bearing the BAP peptide are directed towards ER 
lumen, during their synthesis, therefore the BAP peptide would become accessible 
to BirA enzyme only when the BAP-protein was retro-translocated to the cytosol in 
order to get degraded by the proteasome.  
The engineered BAP-MHC-Iα was used to validate the method, using two HCMV 
derived proteins, US2 and US11 that are well known to induce MHC-Iα 
downregulation by inducing its retro-translocation to the cytosol and proteasome-
dependent degradation. 
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MATERIALS AND METHODS 
 
 
Construction of degradins 
 
By homology with the yeast Hrd3p mutant lacking the NH2-terminal luminal portion 
and the ability to interact with the misfolded protein recognition system, but still 
able to bind the ubiquitin ligase Hrd1p and the other elements of the translocon, 
we created a number of recombinant proteins containing the COOH-terminal 372 
aminoacids of the human SEL1L fused to different recognition domains. The 
recognition domain can be represented by a scFv from an antibody specific for a 
defined antigen or a ligand for a determined receptor. This class of molecules has 
been named as degradins, because they are expected to specifically recognise 
their target proteins within the ER and retain the ability to induce their degradation 
after retro-translocation to the cytosol. 
 
Preparation of scFv degradin specific for FCεRI-α  chain 
 
Total RNA was extracted from the human cell line HEK 293 using the RNeasy Mini 
Kit (Qiagen). After cDNA synthesis with oligo-dT and MuMLV Reverse 
Transcriptase (Invitrogen) using 2 µg of total RNA as substrate, a fragment of 
1138 bp, containing codons 423-794 of human SEL1L (corresponding to positions 
402-773 of the mature protein) was amplified by PCR using primers SEL1L-NheI 
(AGTAGCTAGCGGAAGTGACATTGTACCTCA) and SEL1L-EcoRI 
(TCAGAATTCTTACTGTGGTGGCTGCTGCTCT) and Kod High-Fidelity DNA 
polymerase (Novagen). 
The amplification product was digested NheI/EcoRI and inserted in a pcDNA3 
vector expressing the anti-FcεRI scFv9E1 332 modified by insertion in the NheI site 
of a linker (GGCAAACCAATCCCAAACCCACTGCTGGGCCTGGAT) encoding 
the SV5 tag (GKPIPNPLLGLD). 
The final construct pcDNA3-scFv9E1-SV5-SEL1L was named scFv9E1-degradin. 
A further truncated version of degradin, completely lacking the SEL1L luminal 
portion, was obtained by amplifying the cDNA with primers SEL1L-NheI 
(TCAGCTAGCCTGGTCCATATCAAGTTGGGTGA) and SEL1L-EcoRI. 
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The amplification product was also in this case inserted in pcDNA3-scFv9E1 vector 
using NheI-EcoRI digestions. 
The construct used as a control for ER retention operated by the KDEL retention 
sequence 44,314 was obtained by inserting in the BspEI/XhoI sites of the said 
pcDNA3-scFv9E1 a linker encoding the SV5 tag followed by the KDEL sequence 
(tccggaGGCAAACCAATCCCAAACCCACTGCTGGGCCTGGATAGTACTAAAGA
TGAGCTGtagctcgag). 
The control constructs containing an irrelevant scFv was obtained by substituting 
the HindIII/BspEI cassette encoding the scFv9E1 with the corresponding cassettes 
encoding different scFvs. 
The cassette encoding the anti-FcεRI scFv9E1-degradin was in addition subcloned 
into the pcDNA3-Hygro vector (Invitrogen) for the generation of double transfected 
stable clones. 
scFv9E1-degradin construct was modified by substitution of SV5 tag with another 
tag obtained in the lab.  
 
Preparation of FCεRI α  chain specific ligand degradin 
 
The ligand-degradin expressing vector has been obtained from the previously 
described plasmid pCDNA3-sec-SV5-CH3/CH4, encoding a secretion signal (sec), 
the SV5 tag and human IgE domains CH3-CH4 333.  
This vector was modified by the addition of a linker to introduce a NheI site 
downstream the CH4 domain gene  
Linker sequence: GATCCGGTGGCGCTAGCG 
A HindIII/NheI fragment was excised from the resulting plasmid and transferred to 
the plasmid pcDNA3-scFv9E1-degradin, yielding the construct pcDNA3-sec-SV5-
CH3/CH4-SEL1L that was named LigandFcε-degradin.  
We further produced this construct using a different tag identified in the lab 
amplifying the CH3-CH4-SEL1L fragment using the following plasmids: 
Primer CH3 for with BglII site TCTGAGATCTTGTGCAGATTCGAACCCGAGA 
SEL1L Primer reverse with EcoRI site: 
TCAGAATTCTTACTGTGGTGGCTGCTGCTCT 
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The PCR product was digested with BglII-EcoRI enzymes and ligated in a plasmid 
present in the lab expressing the SEC leader peptide followed by the sequence 
expressing the tag with a BamHI site at the 3’ end compatible with BglII.  
The resulting plasmid is the sec-tag-CH3-CH4-SEL1L (LigandFcε-degradin). 
A truncated form of this construct was generated, lacking the sequence encoding 
the CH3 domain, which is the domain responsible for interaction with FcεRI 287, to 
be used as a non-binding degradin control. 
Amplification of the fragment CH4-SEL1L lacking CH3 domain was performed 
using the SEL1L EcoRI primer and the following forward primer: 
CH4 BglII TGTAAGATCTGGCCCGCGTGCTGCCCCGGAA 
CH4-SEL1L PCR product was ligated in a plasmid pcDNA3-sec-tag using BglII-
ECORI sites obtaining the construct sec-tag-CH4-SEL1L (LigandFcεΔCH3-degradin). 
In order to obtain also for the LigandFcε-degradin the control in which SEL1L lacks 
the domain essential for the induction of ERAD pathway the sequence encoding 
for SEL1L in plasmid sec-tag-CH3-CH4-SEL1L was substituted with the sequence 
encoding for SEL1L TM cyto (SEL1LΔ) obtaining the LigandFcε-SEL1LΔ. 
 
Preparation of SVIP expressing plasmid  
 
The plasmid expressing SVIP protein was obtained by amplifying the SVIP coding 
sequence from human cDNA using the following plasmids: 
Primer forward: TATTCTAGATTCCGGAAACTGTCCACCTAAGTCCACCT 
Primer reverse: TATTCTAGATTATGAAACTGTCCACCTAAGTCCA 
PCR fragment was cloned using HindIII-BspEI digestion in a plasmid that contains 
H6 tag 334. 
 
Preparation of constructs for TGEV inhibition assay 
 
With the aim of inhibit TGEV infective particles formation a specific anti-S protein 
scFv was fused with SEL1L. 
The scFv9E1-degradin construct was digested using a HindIII-BspEI in order to 
substitute the scFv9E1 with scFv6AC3 obtained from pcDNA3-6AC3 swine αSIP 325. 
The resulting construct is the specific S-degradin pcDNA3-scFv6AC3-degradin. 
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As control of ER retention scFv6AC3-KDEL plasmid was constructed by substitution 
of scFv9E1 from pcDNA3-scFv9E1-KDEL with scFv6AC3 using HindIII-BspEI 
digestion. 
The constructs scFv6AC3-degradin, scFv9E1-degradin, 6AC3 swine αSIP and 
scFv6AC3-KDEL were subcloned in pcDNA3- Hygro(+) vector using HindIII-ApaI 
digestions. 
 
Preparation of BAP-HLA-A2 
 
The plasmid pcDNA3-sec-SV5-BAP-CysEMl (Predonzani et al) was modified by 





The intermediate obtained was sec-SV5-BamHI-BAP-NheI. 
RNA was prepared from a pool of lymphocytes derived from different donors using 
Rneasy kit (Qiagen) in order to ensure the presence of the specific HLA sequence. 
Upon standard RT-PCR, HLA-A2 was amplified using the following plasmids: 
oligo A2 EcoRI: taggaattcTCACACTTTACAAGCTGTGAGA 
oligo A2 Nhe: ataggctagcGGCTCTCACTCCATGAGGT 
Both HLA-A2 PCR and the vector pcDNA3-sec-SV5-BamHI-BAP-NheI were 
digested with NheI/EcoRI restriction enzymes and ligated in order to obtain the 
final construct named pcDNA3-sec-SV5-BAP-MHC-Iα. 
pcDNA3.1 plasmids encoding for the HCMV proteins US2 and US11 were kindly 
provided by Domenico Tortorella 102,270,271. 
 
Mutagenesis of US11 expressing plasmid: preparation of US11QL 
 
Starting from plasmid pcDNA3.1-US11 (Domenico Tortorella) mutagenesis was 
performed using Stratagene mutagenesis kit following manufacturer directions with 
the following oligos: 
US11 Q192L forward: 
GTGGCAGTGATTCTAGTGTTTTGGGGGCT 
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US11 Q192L reverse: 
CCCCCAAAACACTAGAATCACTGCCACCA 
 
Cell culture and virus 
 
HEK 293 were used for stable transfections and (expressing SV40 large antigen 
and suitable for transient transfection,335) grown in Dulbecco’s modified Eagle’s 
medium (DMEM, Life Technologies Gibco BRL) supplemented with 10% of fetal 
calf serum (FCS, Life Technologies Gibco BRL). HEK 293 T cells were grown in 
the same conditions as above and were used for transient transfections. 
Baby hamster kidney (BHK21) stably transformed with gene coding for porcine 
aminopeptidase N (BHK pAPN, 336) were grown in DMEM 5% FCS with addition of 
1.5 mg/ml of G418 (Gibco 50 mg/ml) as selective agent.  
HEK 293 cells stably expressing mdα were grown in DMEM 10% FCS using as 
selective agent G418 at 400 µg/ml. 
HEK 293 mdα-scFv9E1-degradin double stable clone (clone G6) was maintained in 
DMEM 10% FCS supplemented with 400 µg/ml of both G418 and hygromicine 
used as selective agents to ensure continuous expression of mdα and scFv9E1-
degradin respectively. 
 
Cells transfection  
 
BHK pAPN stable transfections were performed using 10 µg of pcDNA3 constructs 
previously linearised with a BglII digestion. DNAs were transfected using 
lipofectamine 2000 (Invitrogen) following manufacturer directions. 
BHK pAPN stable clones were maintained in medium containing 400 µg/ml of 
Hygromicine (Invitrogen 50 mg/ml) as selective agent. 
HEK 293 T cells were transiently transfected with calcium phosphate technique 
whereas HEK 293 were used to obtain stable transfected clones. 
Cells were plated in 6-well Petri dishes. Four hours before transfection fresh 
medium was added. 2.5-5 µg of plasmidic DNAs were resuspended in 50 µl of TE 
0.1X (10 mM Tris, 1 mM EDTA) and added to a solution of CaCl2 57.5 mM. 
Further 26 µl of CaCl2 2 M were added and the resulting solution was applied 
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under constant agitation to 250 µl of HBS 2X (280 mM NaCl, 10 mM KCl, 1.5 mM 
NaH2PO4, 12 mM dextrose and 50 mM Hepes). 
16 hours after transfection medium was discarded and serum free medium was 




HEK 293 transfected cells (corresponding to about 5x105 cells) were lysed with 
100 µl of SDS buffer (100 mM TRIS HCl pH 6.8, 4% SDS, 0.2% bromophenol 
blue, 20% glycerol) and subsequently sonicated to disrupt DNA. 
BHK pAPN stable clones were lysed with 100 µl of TNN lysis buffer (100 mM Tris-
Hcl pH 8; 250 mM NaCl; 0.5% NP40) supplemented with Protease inhibitory 
cocktail (PIC, Sigma) according to manufacturer instructions, and were 





A cycloheximide treatment was performed 16 hours after transfection on cells 
cotransfected with mdα and degradins. Cells were treated up to 4 hours with 50 
µg/ml of cycloheximide to analyse mdα stability. 
 
Proteasome inhibitor treatment 
 
HEK 293 stable clones expressing mdα and clone expressing both mdα and 
scFv9E1-degradin (G6 clone) were treated with 20 µM of MG132 proteasome 
inhibitor (50 mM in DMSO, Sigma) or with the same volume of DMSO for 6 hours. 
HEK 293 T cells transiently transfected with plasmids expressing degradins were 











In this study TGEV strain PUR46-MAD 337, was used. 
BHK pAPN stable clones were plated in duplicate in 35 mm dishes in order to 
obtain about 106 cells. Before performing TGEV infection one series of plates were 
used to count the cells in order to ensure the normalization of the results. 
TGEV infection was performed using 1 MOI of TGEV diluted in 500 µl DMEM 2% 
FCS.  
One hour of TGEV internalisation was performed gently shaking every 15 minutes. 




BHK pAPN cells were seeded in 24-well tissue culture plates. Serial dilution of 
supernatants collected from BHK pAPN stable clones infection were made in 
DMEM 2% FCS with 40 µg of DEAE-dextran per ml (Pharmacia). Dilutions 
containing viruses were applied to the cells. After 1 hour of virus adsorption the 
inoculum was replaced with medium containing 2% FCS, 40 g of DEAE dextran 
per ml and 1% agarose. The cells are incubated for 2-3 days at 37° and finally 
fixed with 10% formaldehyde and stained with 0.1% crystal violet. The final step is 
the count of the plaques formed (338 in collaboration with I. Sola and L. Enjuanes-
Centro Nacional de Biotecnologia-Madrid 324,325). 
 
 
EndoH and PNGase F samples deglycosylation 
 
In order to visualise protein localisation we used two different deglycosylating 
enzymes: EndO Hf and PNGaseF (NEB, New England Biolabs, Beverly, MA). 
EndoO Hf cuts N-glycosylation ER dependent and the sensitivity to this enzyme 
reflects an ER localisation whereas PNGase act on all types of N-glycosylation. 
Samples containing the glycoprotein are heat denatured with 10% of denaturing 
buffer at 100°C for 10 minutes. 10% of specific buffer (G5 0.5 M sodium citrate pH 
5.5 for ENDO Hf and G7 sodium citrate PH7.5 for PNGase F) was added and for 
the reaction of PNGase F 10% of NP40 must be added. Samples were incubated 
with a proper amount of enzyme for 1 hour at 37°C.  
Materials and methods  
 69 
After another denaturation with SDS containing sample buffer the samples were 
loaded on SDS-PAGE. 
 
 
Western blot analysis 
 
Cell extracts and supernatants were loaded on a SDS-Page and transferred on 
PVDF membrane (Millipore) previously activated in methanol. Transfer on PVDF 
membrane was done in Tris-Glycine buffer (Tris 25 mM, glycine 192 mM and 20% 
methanol).  
To detect degradin expression both in transient and stable transfections primary 
antibody used was mAb anti SV5 tag antibody (Invitrogen) and mAb anti tag 
(produced in our lab). 
FCεRI-α chain expression was detected using mAb 9E1, expression of BAP-MHC-
Iα and sα-SV5-BAP was detected using anti-SV5 antibody. . 
TGEV S protein expression was detected with murine mAb 1D.G3, TGEV M and N 
protein expression were detected with murine mAbs 25.22 and 3D.C10 
respectively 318,338,339,340. 
In all cases secondary antibody used was anti mouse Fcγ peroxidase labeled 
(Jackson). 
To normalize the amount of extract loaded on the gels, blots were in addition 
incubated with anti-actin antibody (Sigma) and with a goat anti rabbit HRP-
conjugated (Thermo Scientific). 
Upon deglycosylation treatment with EndoHf and PNGaseF enzymes, both sdα 
and mdα were detected using a rabbit polyclonal antibody against Fcγ (DAKO) 
and by the use of a goat anti rabbit antibody HRP-conjugated (Thermo Scientific). 
 
ELISA screening of swine a SIP 6AC3 expressing clone 
 
BHK-pAPN cells stably transfected with a SIP version of 6AC3 antibody were 
selected analyzing supernatants.  
96 multi well Maxisorp ELISA plates (Nunc) were coated with goat anti porcine IgA 
1 µg/ml (Serotec) for 2 hours at 37°. After 3 washes with PBS containing tween 
0.05% (PBS-tween), plates were blocked with and BSA 1% in PBS-tween. 
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Supernatants of a 96 multiwell plates of BHKpAPN transfected with 6AC3αSIP 
were collected and incubated on plate for 1h 
Plates were washed and incubated with a goat anti porcine IgA peroxidase labeled 
1 µg/ml (Serotec). Reaction was performed using tetramethylbenzidine (TMB) 
peroxidase substrate (Sigma). 
 
In vivo biotinylation to detect retro-translocated molecules 
 
HEK 293 T cells were transfected with 0.5 µg of BirA plasmid, 0.5 µg of plasmid 
expressing SV5-BAP-MHC-Iα and 1 µg of US2 or US11 expressing plasmid. 16 
hours after transfection medium was discarded and cells were incubated for 24 
hours with biotin 100 µM (Sigma) diluted in serum free medium. 
To study retro-translocation induced by degradins HEK 293T cells were 
transfected with 0.5 µg of BirA plasmid, 2.5 µg of sα-SV5-BAP and 2.5 µg of 
degradin expressing plasmid. Also in this case serum free medium was applied 16 
hours post tranfection and biotin serum free medium was added for 24 hours. 
Experiments of detection of biotinylated molecules during proteasome inhibitor 
treatment were performed as follows: cells were transfected with the same 
quantity of plasmids just described. 16 hours after transfection medium was 
discarded and serum free medium containing biotin was added with 20 µM of 
MG132 proteasome inhibitor (Sigma) or the same volume of DMSO. Proteasome 
inhibitor treatment was carried on for 6 hours in presence of biotin. Afterwards 
cells were lysed with Sample buffer and supernatants were collected. 
 
Gel retardation assay 
 
Lysates of HEK 293T cells transfected with SV5-BAP-MHCα or sαBAP were 
incubated or not for 1hour at RT with 1 µg of purified streptavidin (Invitrogen). After 
streptavidin incubation samples were loaded on SDS-Page under denaturing 
conditions and blotted on PVDF membrane (Millipore). 
Detection of protein was performed using anti SV5 mAb; biotinylated molecules 
can be discriminated from the non-biotinylated ones because they are bound very 
strongly by streptavidin. Binding to streptavidin changes migration of biotinylated 
molecules that migrates as higher molecular weight protein. 
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Samples incubated and not incubated with streptavidin were loaded in parallel to 
determine aproximatively the percentage of molecules shifted because of their 
biotinylated status. 
 
ELISA detection of biotinylated retro-translocated molecules 
 
96 multi well Maxisorp ELISA plates (Nunc) were coated with mAb anti-SV5 in 
carbonate buffer. Lysates of 293 cells were applied and incubated for 1 h. 
Biotinylated molecules were detected with Streptavidin HRP-conjugated 
(Jackson). 
 
Flow cytometry assay 
 
HEK 293-mdα clone was analysed by flow cytometry using a FACS-CaliburTM 
(Becton Dickinson). The expression of the receptor was detected using as primary 
antibody mAb 9E1 and anti mouse IgG fluorescein conjugated (KPL, Kirkegaard 
and Perry Laboratories, Gaithersburg, MD) as secondary antibody. 
In order to verify the intracellular localisation of degradins a FACS analysis was 
performed. HEK 293T cells transiently transfected with plasmids expressing 
degradins were analysed using as primary antibody mAb anti-SV5 and as 
secondary antibody a goat anti mouse IgG fluorescein conjugated (KPL). 
 
IgE binding assay on mdα expressing clones 
 
FACS analysis was performed to study mdα binding of IgE in mdα expressing 
clone and mdα-degradin double stable transfected clone (G6 clone). The analysis 
was done using purified human IgE (Calbiochem, Canada) and as secondary 
antibody a FITC-conjugated goat anti human IgE (DAKO) was used. 
 
S35 pulse-chase experiment 
 
293 cells were transfected using calcium phosphate technique; 16 hours after 
transfection medium was discarded and cells were starved for 30 minutes with 
DMEM Methionine/Cysteine free with 10% of dialyzed FCS and biotin. 
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Following starvation cells were labeled for 30 minutes with 35S 
Methionine/Cysteine 200 µCi/ml and afterwards medium was discarded and 
complete DMEM was added to chase the radioactive label. Chase period was 
performed for different times (from 30 minutes to 4 hours) in presence or absence 
of proteasome inhibitor MG132 (Sigma). 
 
Immunoprecipitation of S35 labeled extracts 
 
Cell lysates obtained using SDS electrophoretic sample buffer were diluted with 
400 µl of TNN lysis buffer and digested with DNaseI for 1h to disrupt DNA and 
ensure the immunoprecipitation to work properly. Samples were 
immunoprecipitated using anti SV5 (1:500) or with 9E1 mAb (1:250) and 25 µl of 
Protein A-sepharose for 1 h. This suspension was applied to micro Bio-spin 
chromatography columnns (Biorad); columns were washed three times with TNN 
and twice with PBS. Bound proteins were eluted from the columns using 50 µl of 





Design and construction of degradins 
 
With the aim of specifically targeting proteins within the secretory pathway for 
degradation, a new class of fusion molecules was designed and constructed, 
which we termed degradins. Degradins contain a target recognition moiety specific 
for a particular target and a degradative moiety able to induce target degradation 
(Figure 1A). 
The recognition moieties can be derived from many different sources (monoclonal 
antibodies, antibody fragments derived from libraries, antibody heavy chains V 
regions, specific binding peptides, ligands or receptors) characterised by a high 
specificity for the target. 
In my construct the degradative moiety is represented by the C-terminal 372 
residues of SEL1L (positions 402-773 of the mature protein), which is an adaptor 
protein in the ERAD pathway that binds the substrate and both HRD1 and Derlin-1 
proteins. SEL1L is therefore able to link substrate recognition with substrate retro-
translocation. 
This portion of SEL1L was chosen as degradation moiety after sequence 
alignment with yeast and C. elegans homologues, Hrd3p and SEL1 respectively. 
Hrd3p contains two regions in its luminal domain; the first one, localised at the N-
terminus (residues 1-390), is probably involved in substrate recruitment, while the 
second one (residues 390-767) mediates the stabilisation of Hrd1p ubiquitin ligase 
avoiding its autoubiquitinylation and degradation 155. In addition indications about 
the right choice of SEL1L domain essential for the induction of protein degradation 
came out from studies in which the human SEL1L C-terminal portion (residues 
373-end) was assessed to be essential for interactions with HRD1, OS-9 and XTP-
3B 183. Those interactions seem to be crucial for dislocation, ubiquitinylation and 
the subsequent proteasome-dependent degradation. 
The resulting degradin is an ER-resident type I transmembrane protein; its binding 
moiety is localised at the N-terminus on the luminal side and allows the recognition 
of ER localised target proteins (proteins in transit through the ER or ER resident). 
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A target molecule would be engaged within the ER by the recognition-specific 
domain of a degradin and would be committed for the degradative pathway by the 
SEL1L moiety which promotes the ER to cytosol dislocation process. 
The possibility to use different target recognition moieties provides the system a 
high degree of flexibility. Therefore, whichever secretory or membrane-bound 
protein can theoretically be directed towards proteasome-mediated degradation, 
once a specific ligand is identified. 
 
 
Figure 1: A) schematic representation of degradin obtained by the fusion of a specific target 
recognition moiety with SEL1L (402-773) portion 
B) Illustration of presumed degradin activity. Degradin is an ER membrane anchored protein with 
both recognition and degradative moieties facing the lumen of the ER. Thus, the target recognition 
moiety is able to recognise either secretory or membrane tethered target proteins within the ER. 




As a model protein to be targeted for degradation the FcεRI-α chain was chosen 
(Figure 2A); this model gave me the opportunity to test the degradin system on 
two forms of FcεRI-α chain previously obtained in our lab, one soluble and the 
other one membrane anchored. Both versions contain the FcεRI-α chain 
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extracellular domains D1 and D2 and are fused through a five aminoacids linker to 
the CH3 dimerization domain derived from human IgG1 heavy chain (γ1). The 
resulting constructs encode a soluble receptor protein (sdα 332) or membrane 
bound receptor protein (mdα; Vangelista, Cesco Gaspere unpublished work) 
depending whether the CH3 was derived from the secretory or membrane bound 
γ1 heavy chain respectively. Both proteins are expressed as dimers as shown in 




Figure 2: Figure: A) FcεRI is constituted by one β chain, two γ chains and one α chain. FcεRI-α 
chain contains two extracellular domains: D1, and D2 responsible for IgE binding. IgE binds the 
receptor through its Cε3 domain. 
B) Schematic representation of the soluble dimeric version of FcεRI-α chain obtained by fusing 
domains D1 and D2 of α chain with the secretory γ1CH3 dimerization domain, sdα 
C) Schematic representation of membrane version of FcεRI-α chain that contains, domains D1 and 
D2 fused to the membrane γ1 CH3 domain, mdα. 
 
 
Besides the possibility to test the degradin system on either soluble or membrane 
anchored proteins, the choice of FcεRI-α chain allowed me to test two different 
target recognition moiety, one represented by a scFv (scFv-degradin) and the 
other by the FcεRI-α chain ligand, the IgE molecule (Ligand-degradin). 
A monoclonal antibody against domain D1 of FcεRI-α chain, 9E1, was previously 
produced in our lab (Vangelista, Cesco Gaspere unpublished work).  
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From mAb 9E1 a single chain antibody molecule was obtained through 
amplification of the VL and VH domains and assembly in the VL-VH orientation 
with a linker to maintain the association between the two domains (scFv9E1). 
The degradin containing the target recognition moiety scFv9E1 was obtained by 
fusing it to the SEL1L 402-end portion degradative moiety. The resulting scFv9E1-
degradin is specific for FcεRI-α chain (Figure 3A). 
As a control of degradin specificity, a scFv-degradin with an irrelevant recognition 
moiety was produced (irrelevant-degradin; Figure 3B). 
An intrabody with the ER retention signal KDEL was also constructed using 
scFv9E1; the obtained construct scFv9E1-KDEL would be able to bind to FcεRI-α 
chain, but lacking the degradative moiety it should only cause a retention in the ER 
compartment (Figure 3D). I used this intrabody to compare the effect of simple 
retention with the possible effect of degradation induced by degradins. 
To facilitate the detection of degradins, the 12 aminoacid-long SV5 tag was 
inserted between the recognition and the SEL1L moieties (Figure 3A and 3B) or 
between the recognition moiety and the KDEL sequence in the case of scFv9E1-
KDEL (Figure 3D). 
The FcεRI-α specific Ligand-degradin was constructed using as recognition moiety 
the CH3 and CH4 domains of the human ε heavy chain that are known to bind 
efficiently the FcεRI-α 287. This FcεRI-α specific Ligand degradin was named 
LigandFcε-degradin (LFcε-degradin). In this case the SV5 tag was inserted at the N-













Figure 3: Schematic representation of constructs. A) degradin specific for FcεRI-α chain where the 
recognition moiety is the mAb 9E1-derived scFv9E1. B) degradin with irrelevant specificity obtained 
by substitution of scFv9E1 with scFvirr. C) The Ligand-degradin where the FcεRI-α chain specific 
recognition moiety is represented by CH3 and CH4 domains of IgE. D) Control construct for ER 
retention; constituted by the scFv9E1 fused to the C-terminus to a KDEL sequence. 
 
Degradin expression and localisation 
 
The plasmids encoding the constructs described above were transiently 
transfected into HEK 293 T cells and the expression of degradins was tested on 
extracts and supernatants.  
Extracts and supernatants were loaded on SDS-PAGE and Western blotting was 
performed using an anti-SV5 antibody to check their expression. 
As shown in figure 4A, degradins were well expressed and were found only at the 
intracellular level, whereas scFv9E1-KDEL, in spite of the presence of the KDEL 
signal for ER retention, was detected in large amounts also in supernatants 
(Figure 4B). 
Since the mAb 9E1 VH domain contains a glycosylation site, scFv9E1-KDEL can be 
visualised in Western blotting as two separate bands corresponding to the 
glycosylated and the non-glycosylated forms (Figure 4A and B). The glycosylation 
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pattern was confirmed treating supernatants of HEK 293 T cells expressing 
scFv9E1-KDEL with PNGaseF, which is able to remove all glucidic side chains from 
glycoproteins (Figure 5C). PNGaseF treatment caused the disappereance of the 
upper band of scFv9E1-KDEL, but did not change the mobility of the lower band, 
which should therefore correspond to the non-glycosylated form (Figure 5C). It 
appears from this experiment that scFv9E1-KDEL is only partially glycosylated due 
to an inefficient site of glycosylation.  
All degradins are visualised as two separate bands, corresponding to the 
glycosylated and partially glycosylated forms due to the presence in the SEL1L 
sequence of two sites of glycosylation (position 411 and 587 of the entire SEL1L) 
maintained in the SEL1L (402-end) fragment of degradins (Figure 4A, see also 
EndoH treatment in Figure 5B). 
In addition scFv9E1-degradin also contains the 9E1 VH glycosylation site, whereas 




Figure 4: Western blotting on extracts (A) and supernatants (B) of HEK 293 T cell transiently 
transfected with plasmids encoding degradins or the intrabody scFv9E1-KDEL. Expression of 
transfected proteins was detected by mAb anti-SV5. 
C) The low efficiency of glycosylation of 9E1 VH was confirmed by treating supernatants of cells 




The different degradins were expected to be confined within the cell and in 
particular because of the activity of SEL1L transmembrane domain in establishing 
ER retention 183, they were expected to localise completely in the ER. 
In order to confirm degradin localisation a cytofluorimetric analysis was done on 
HEK 293 T cells transiently transfected with degradins or with an SV5 tagged 
membrane version of IgE (tmLIgE, 330) as a positive control of both, transfection 
and anti-SV5 antibody detection. 
As shown in figure 5A, all types of degradins, either irrelevant, scFv9E1 or LFCε, 
were not detected on the cell surface while the SV5 tagged membrane IgE was. 
To further assess degradin intracellular localisation we performed a 
deglycosylation treatment with the endoglycosidase enzyme EndoH. EndoH 
deglycosylates only molecules that bear a high mannose N-glycan, characteristic 
of ER localised proteins, whereas Golgi-dependent glycosylated proteins are 
resistant to EndoH.   
As shown in figure 5B all degradin types demonstrated to be fully sensitive to 




Figure 5: Intracellular degradin localisation was confirmed by cytofluorimetric analysis using mAb 
anti-SV5 (A). ER localisation was assessed by deglycosylation treatment with EndoH enzyme 

















scFv9E1-degradin causes a strong decrease of the soluble form of FcεRI-α  
chain (sdα) 
 
In order to analyse degradin activity on the soluble version of the FcεRI-α chain 
(sdα), HEK 293 T cells were transiently cotransfected with plasmids encoding sdα 
and each one of the different degradins. 
The effect of degradins on sdα secretion and eventual retention in the ER, due to 
the ER localisation of degradins, was analysed by Western blotting in cellular 
extracts and supernatants.  
To compare the effect in decreasing target protein accumulation induced by 
degradins with simple ER retention, such as that mediated by the KDEL retention 
signal, scFv9E1-KDEL was also cotransfected with sdα. 
As shown in figure 6A lane 1, scFv9E1-degradin blocked completely sdα secretion 
as no molecules can be detected in supernatants. 
In contrast the irrelevant-degradin, in which the scFv moiety does not recognise 
the target, allows sdα secretion (lane 3), confirming the specificity of scFv9E1-
degradin. 
The scFv9E1-KDEL allowed a small amount of sdα to be secreted as visualised in 
supernatants of figure 6A, lane 2: this is most likely due to the incomplete 
intracellular retention of scFv9E1-KDEL, which can be detected in considerable 
amounts in the supernatant. 
The detection of sdα in the supernatant when coexpressed with scFv9E1-KDEL led 
us conclude that scFv9E1-degradin is more efficient in preventing sdα secretion. 
When looking at the intracellular content (Figure 6B lane 2), it is possible to see 
that scFv9E1-KDEL caused a large accumulation of sdα in the ER, and prevented 
its transit through the Golgi, as can be deduced by the absence of the higher 
molecular weight glycosylated forms. On the contrary, very little target protein was 
detected in cellular extracts of scFv9E1-degradin transfected cells (Figure 6B lane 
1). Thus, together with sdα absence in supernatants, this result suggests that the 
degradin induced active degradation of the target, sdα. 
The ER localisation of the sdα lower molecular weight form was confirmed by 
treating sdα accumulated protein when coexpressed with scFv9E1-KDEL with the 
endoglycosydase EndoH that, as described previously, is not able to deglycosylate 
proteins with Golgi-dependent glycosylation. 
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Since mAb 9E1 demonstrated to be much less sensitive in the detection of 
deglycosylated FcεRI-α chain molecules, in this case an anti human Fcγ antibody 
(DAKO) was used. As shown in figure 6C when coexpressed with scFv9E1-KDEL 
sdα is fully deglycosylated by EndoH confirming its ER localisation. 
 
 
Figure 6: Analysis of scFv9E1-degradin activity on sdα. Detection of sdα using 9E1 mAb on extracts 
(A) and supernatants (B) of HEK 293 T cells cotransfected with sdα and the indicated proteins. 
Detection of degradins was performed using anti-SV5 antibody. Anti-actin antibody was used as 
loading control. 
C) Extracts of cell expressing sdα and scFv9E1-KDEL were treated or not treated with EndoH. sdα 
was detected using a rabbit anti human Fcγ (DAKO) and a goat anti rabbit Ab peroxidase 
conjugated (Thermo Scientific). 
 
scFv9E1-degradin causes a strong decrease on membrane version of FcεRI-α  
chain (mdα) 
 
In order to obtain further evidences on the applicability of degradins, the system 
was tested on the membrane bound version of the same FcεRI-α chain (mdα). 
Analysis of mdα levels was done by Western blotting of total extracts of HEK 293 
T cells cotransfected with a plasmid encoding mdα and different types of degradin 
plasmids as reported in figure 7A. As an additional control mdα was also 
cotransfected with a vector without any insert (pcDNA3 mock). 
As shown in figure 7A, scFv9E1-degradin caused a strong decrease in the amount 
of mdα, compared to pcDNA3 mock and to irrelevant-degradin (compare lane 4 
with lanes 1 and 2 respectively). When coexpressed with scFv9E1-degradin, mdα 










































































localised in the ER, that has not yet undergone Golgi-dependent glycosylation 
(see also Figure 7B). 
The expression of the irrelevant-degradin did not block mdα trafficking to the Golgi 
apparatus. In fact most of mdα acquired a complete glycosylation state and 
migrated as a higher molecular weight protein. 
When compared to the cotransfection with a pcDNA3 mock, irrelevant-degradin 
caused a partial impairment in mdα expression.  
This effect could be the consequence of the residual activity of the SEL1L 
fragment of degradins in recognising misfolded proteins, therefore increasing their 
degradation. Alternatively, degradins could alter the ER environment and induce 
an UPR response. 
However, a very large difference between irrelevant-degradin and scFv9E1-
degradin activities was clearly visualised, confirming the essential role of the target 
recognition moiety. 
When coexpressed with scFv9E1-KDEL mdα was completely retained in the ER but 
with a small decrease in the protein amount indicating a compromised degradative 
activity. This result is visualised in figure 7A, lane 3, where only the incomplete 
glycosylation form of mdα was detected. Interestingly, scFv9E1-KDEL displayed a 
retention activity that was more efficient on mdα than on sdα (compare figure 7A 
with figure 6A in which sdα is partially secreted). It is likely that scFv9E1-KDEL 
forms a complex with sdα that can be secreted, while the complex formed by 
scFv9E1-KDEL and mdα would not be able to proceed to the Golgi, due to the 
membrane anchoring effect exerted by mdα transmembrane domain. 
Also for membrane bound proteins, therefore, the impairment of target protein 
expression seems to be specifically induced by scFv9E1-degradin upon the 
recruitment of the target through the recognition moiety. 
The ER localisation of mdα lower molecular weight form was confirmed by treating 
mdα coexpressed with scFv9E1-KDEL with the endoglycosydase EndoH. As shown 
in figure 7B when coexpressed with scFv9E1-KDEL, mdα was fully deglycosylated 




The degradation of mdα induced by scFv9E1-degradin was measured by blocking 
protein synthesis 16 hours after transfection with cycloheximide at 50 µg/ml and by 
anlysing cell extracts at different time points (up to 4 hours) by western blotting.  
When coexpressed with scFv9E1-degradin mdα was almost completely 
disappeared after 30 minutes, whereas when coexpressed with irr-degradin it took 
at least 4 hours to reach a similar level of reduction (Figure 7C).  
A similar result was obtained when cells were pulsed for 30 minutes with [35]S-
Methionine and chased up to 4 hours. 
The amount of mdα at the starting point was already decreased in the presence of 
scFv9E1-degradin, suggesting a very fast degradation induced by degradins. 
A decrease in the amount of mdα was visible after 4 hours when expressed with 
the irr-degradin, whereas an almost complete absence of mdα was visualised after 
only 2 hours when expressed with scFv9E1-degradin (Figure 7D). 
These results further suggest that scFv9E1-degradin actively induces degradation 










Figure 7: A) scFv9E1-degradin effect on mdα. Extracts of HEK 293 T cells cotransfected with 
plasmids encoding mdα and the indicated proteins were analysed by Western blotting using 9E1 
mAb to check mdα expression. Anti-SV5 antibody was used to detect degradins and scFv9E1-
KDEL. Anti-actin antibody was used as loading control B) Extracts of cell expressing mdα and 
scFv9E1-KDEL were treated or not treated with EndoH. mdα was detected using a rabbit anti human 
Fcγ (DAKO) and a goat anti rabbit Ab peroxidase conjugated (Thermo Scientific). 
C) Measurement of mdα half-life when coexpressed with scFv9E1-degradin or with irr-degradin. 16 
hours after transfection cells were treated with cycloheximide 50 µg/ml for the indicated times. 
D) Pulse-chase experiment with [35S]-Methionine. After a pulse of 30 minutes cells were chased for 




Activity of the Ligand-degradin (LFcε -degradin) 
 
To further validate the method, I investigated the possibility to induce degradation 
of the FcεRI-α receptor protein exploiting the specificity of its ligand.  
A Ligand-degradin (LFcε-degradin), containing the human ε-CH3 and ε-CH4 
domains, specific for the interaction with the FcεRI-α chain, was tested by 
cotransfection with plasmids encoding both mdα and sdα followed by western 
blotting analysis. 
As shown in figure 8A and B, LFcε-degradin caused a strong decrease in sdα levels 
even if, when compared to scFv9E1-degradin, seemed to have lower effect in 
blocking sdα secretion (Figure 8A compare lane 2 and 3).  
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As shown in figure 8B, lane 2, analysis of the cellular extracts showed that LFcε-
degradin did not cause sdα ER accumulation. 
The same effect of large target protein decrease caused by LFcε-degradin was 
observed also for mdα; consistently with the partial secretion of sdα, the residual 
mdα can be visualised in two different glycosylation forms that could reflect mdα 
capability to reach the Golgi apparatus (Figure 8C, lane 2). 
 
Figure 8: LFcε-degradin efficiency was compared with scFv9E1-degradin efficiency by Western 
blotting analysis on supernatants (A) and extracts (B) of HEK 293 T cells transiently transfected 
with sdα encoding plasmid or on extracts of cells transfected with mdα encoding plasmid (C). 9E1 
mAb was used to check sdα and mdα expression, anti-SV5 antibody was used to check degradin 
expression and anti-actin antibody was used as loading control. 
 
 
Degradins do not affect the accumulation of an irrelevant protein 
 
The specific effect of degradins was further investigated by testing their activity on 
an exogenous irrelevant protein; for this purpose we cotransfected a secretory 
tagged version of a scFv (scFv1E10 330,341) with degradins. 
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Degradins did not affect neither the expression nor the secretion of the irrelevant 
protein. As shown in figure 9, coexpression with a pcDNA3 mock or with each one 
of the degradins resulted in comparable expression levels of the irrelevant protein. 
 
 
Figure 9: Effect of degradins expression on an irrelevant protein. Western blotting analysis was 
performed on HEK 293 T cell trasfected with plasmid encoding the irrelevant secretory control 
protein scFv1E10 with each one of the plasmids encoding degradins or with pcDNA3 mock. 




The relevant role of the SEL1L moiety 
 
In order to further investigate the requirement of the SEL1L luminal region for the 
degradin activity, a control construct containing a deleted version of the SEL1L 
luminal domain and maintaining only the transmembrane and cytosolic portions of 
SEL1L (SEL1LΔ) was produced (scFv9E1-SEL1LΔ Figure 10B). The SEL1L ER 
luminal region has been described to interact with components of the ERAD 
machinery (in particular with the ubiquitin ligase HRD1) and to be essential for the 
induction of misfolded protein degradation. Therefore constructs containing 
SEL1LΔ should not induce target degradation but instead only intracellular target 
retention. 































As a further control of LFcε-degradin specificity, a deleted version of the ligand was 
produced (LFcεΔ-degradin Figure 10E). This construct maintains only the human 
εCH4 domain but lacks the human εCH3, essential for FcεRI-α chain binding 287. 
The scFv9E1-degradin, scFv9E1-SEL1LΔ and LFcε-degradin constructs were 
produced either using the SV5 tag or using a Tag obtained in our lab whereas LFcε-





Figure 10: Schematic representation of: A) scFv9E1-degradin; B) the control scFv9E1-SEL1LΔ 
degradin in which the target recognition moiety is maintained whereas the degradation moiety was 
deleted (dotted line) but maintains the transmembrane (TM) and cytosolic portions. 
C) LFcε-degradin; D) mutated Ligand-degradin with the luminal part of SEL1L deleted (dotted line) 
as in B (LFcε-SEL1LΔ); E) LFcεΔ–degradin (deleted Ligand-degradin) that lacks the εCH3 (dotted line) 
responsible of binding to FcεRI-α chain,  
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In order to compare scFv9E1-degradin and scFv9E1-SEL1LΔ activities each one of 
these two proteins or the irrelevant-degradin were coexpressed with sdα. As 
shown in figure 11A while irrelevant-degradin allowed sdα to be secreted in the 
supernatant (lane 2), both scFv9E1-SEL1LΔ and scFv9E1-degradin strongly inhibited 
sdα secretion (lane 3 and 4 respectively). 
At the intracellular level however, a difference between scFv9E1-SEL1LΔ and full 
length degradin activities could be appreciated. As visualised by Western blotting 
on cellular extracts (Figure 11B) while scFv9E1-SEL1LΔ produced a large 
intracellular accumulation of sdα in the ER, comparable to that caused by scFv9E1-
KDEL, scFv9E1-degradin did not (compare lanes 4, 5 and 3 respectively).  
Taken together these results strongly suggest that the SEL1L luminal domain is 
essential to induce an active degradation of the target, since the presence of the 
transmembrane and cytosolic domains alone only caused intracellular 
accumulation.  
 
The deleted Ligand-degradin (LFcεΔ-degradin) and SEL1L deleted version of 
Ligand-degradin (LFcε-SEL1LΔ) were also analysed for their effect on sdα 
expression and compared to the activity of the full length LFcε-degradin.  
As shown in figure 11C, sdα secretion as expected was not impaired by LigandFcεΔ-
degradin (lane 2), due to its inability to bind FcεRI-α chain whereas sdα secretion 
was completely prevented by both LFcε-degradin and LFcε-SEL1LΔ (lanes 3 and 4).  
However, while only traces of sdα can be detected intracellularly when 
coexpressed with LFcε-degradin, LFcε-SEL1LΔ produced a large ER retention of sdα 
(Figure 11D compare lanes 2 and 4).  
This result is consistent with an important role of the SEL1L luminal region for the 












Figure 11: Western blotting of extracts and supernatants of HEK 293 T cells cotransfected with sdα 
encoding plasmid and plasmids encoding the proteins indicated on the figure. A-B) Comparison 
between scFv9E1-degradin and scFv9E1-SEL1LΔ activities on sdα expression  
C-D) LigandFcε-degradin activity was compared with LigandFcεΔ-degradin and LigandFcε-SEL1LΔ 
controls. For sdα detection mAb 9E1 was used and anti-tag mAb was used for degradin detection. 
Anti-actin antibody was used as loading control. 
 
 
Similar effects of the deleted degradin were also obtained with the membrane 
version of FcεRI-α chain (mdα). 
As shown in figure 12A lane 4, scFv9E1-SEL1LΔ did not impair mdα expression, 
but instead displayed a retention activity as visualised by the presence of the ER 
glycosylated form of mdα, similar to scFv9E1-KDEL (compare lanes 4 and 5).  
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As shown in figure 12B lane 4, also the LFcε-SEL1LΔ produced ER retention 
although not complete, and partial activity in decreasing mdα accumulation 
probably correlated to ER stress. The LFcεΔ-degradin instead, did not have any 
effect on mdα expression and localisation, consistently with its inability to bind the 
target (Figure 12B, lane 2). 
 
Figure 12: Western blotting of extracts of HEK 293 T cells cotransfected with mdα and plasmids 
encoding the indicated proteins. A) Comparison between scFv9E1-degradin and the deleted 
degradin scFv9E1-SEL1LΔ  
B) The LigandFcε-degradin was compared with the deleted Ligand (LFcεΔ-degradin) and with the 
deleted degradin (LFcε-SEL1LΔ) controls. For mdα detection mAb 9E1 was used, anti-tag mAb was 
used for degradin detection and anti-actin antibody was used as loading control. 
 
Degradins-induced degradation and the proteasome machinery 
 
The design of degradins was based on the assumption that the activity of SEL1L 
in inducing misfolded protein degradation through the ubiquitin proteasome 
pathway would be maintained. Therefore target degradation induced by degradins 
would take place by recruiting ubiquitin ligases and the proteasomal machinery.  
Results 
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To confirm this assumption I used the proteasome inhibitor MG132 in cells co-
expressing degradins and the target, in order to block proteasome dependent 
degradation. 
For this purpose HEK 293 T cells were transiently transfected with mdα and 
degradins encoding plasmids and, 16 hours after transfection, treated with MG132 
for 6 hours. The outcome of this experiment was that MG132 addition caused an 
increased intracellular accumulation of target protein, an effect that was more 
evident with scFv9E1-degradin rather than with LFcε-degradin (Figure 13A).  
In particular, due to the ER localisation of scFv9E1-degradin, the increased amount 
of mdα was almost completely retained in the ER and only a small portion was 
detected in the terminal glycosylated form. The accumulation of glycosylated mdα 
molecules during MG132 treatment resulted in the ability of a certain amount of 
mdα to reach the Golgi where the its N-glycosylation is modified. 
The inhibition of degradation caused by the proteasome inhibitor MG132 
confirmed that degradin-induced degradation was at least in part dependent on the 
proteasome activity. The incomplete rescue in protein expression could be due to 
an involvement of autophagy or by an induction of autophagy, caused by MG132 
treatment. It has been reported that autophagy induction seems to protect the cell 
form death in situations in which the proteasome is inhibited (reviewed in 342). 
This could be the main reason why MG132 treatment did not result in a complete 
inhibition of degradation since substrates of ERAD (in this case mdα) would be re-
routed to autophagy during proteasome inhibition. 
This possibility could be investigated by treating cells with proteasome and 
autophagy inhibitors. 
 
When the same experiment was performed on sdα no increase was visible upon 
MG132 treatment (data not shown). 
Since deglycosylation is an important step during proteasome-dependent 
glycoprotein degradation we decided to use sα-SV5-BAP, a soluble SV5 tagged 
version of α chain (αD1D2-SV5-BAP 330; see also figure 26A) that can be detected 
using anti-SV5 antibody. Anti-SV5 antibody should detect all sα-SV5-BAP 
molecules, either glycosylated and deglycosylated, while mAb 9E1 displayed a 
much reduced affinity for deglycosylated FcεRI-α chain molecules.  
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As expected, degradins were still functional against sα-SV5-BAP since the 
inhibition of sα-SV5-BAP secretion was evident with both scFv9E1-degradin and 
LFcε-degradin (Figure 13B). 
Although MG132 treatment did not produce an increase in sα-SV5-BAP secretion 
in the presence of degradins, I found that, interestingly, the non-degraded 
accumulated sα-SV5-BAP molecules migrate as lower weight band (Figure 13B) 
corresponding to the deglycosylated molecules (data not shown). 
In the absence of proteasome inhibitors these deglycosylated molecules were very 
poorly represented, whereas once accumulated upon treatment with MG132, their 
detection was enabled (Figure 13C).  
As a further analysis the different stability of degradin in the presence or absence 
of its target (mdα) was also assessed. As visualised in figure 13D scFv9E1-
degradin stability seemed to be somehow reduced by the coexpression with the 
target mdα, while no differences were visible with the irr-degradin. This indicates 
that only a small fraction of degradin was degraded, while most of it could exhibit a 






















Figure 13: A) mdα was coexpressed in HEK 293 T cells with one of the indicated proteins: 16 hours 
after transfection cells were treated for 6 hours with 20 µM MG132. mdα was detected using mAb 
9E1 and as loading control anti-actin antibody was used. 
B-C) The same experiment was performed coexpressing sdα with the indicated proteins; 
supernatants (B) and extracts (C) were analysed by Western blotting using mAb anti-SV5 and as 
loading control anti-actin antibody. 
Degradin expression was analysed in the presence or absence of its target mdα (D) 
 
Use of the endogenous ERAD inhibitor: SVIP 
 
An endogenous ERAD inhibitor known as SVIP has been described. SVIP is a 
cytosolic protein, anchored to the ER membrane through myristoylation 233. It has 
been described to form a complex with Derlin-1 and p97 and to reduce association 
of ERAD substrates with p97, thus avoiding protein ubiquitinylation and 
degradation 232. 
To test the ability of SVIP to inhibit degradin-mediated target degradation (what 
would constitute a further confirmation of proteasome involvement in this process) 
HEK 293 T cells were transfected with plasmids encoding mdα, degradins 
(scFv9E1-degradin, irrelevant and LFcε-degradin) and SVIP. An irrelevant protein 
was transfected in the samples in which SVIP is not present, in order to have the 
same amount of exogenous mRNA. 
Results 
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Figure 14 shows that SVIP expression led to an increase in the intracellular level 
of mdα either when coexpressed with scFv9E1-degradin or when coexpressed with 
LFcε-degradin, although increase in mdα expression was more evident in the case 
of the LFcε-degradin, showing accumulation of both completely glycosylated and 
incompletely glycosylated bands in agreement with the result obtained with 
MG132 (compare Figure 14 and 13A). This result suggests that SVIP through its 
activity in inhibiting retro-translocation is able to partially block target degradation 




Figure 14: Analysis of SVIP activity on degradin-induced degradation. mdα was coexpressed in 
HEK 293 T cells with degradins and SVIP or with a control protein. mAb 9E1 was used to check 




Degradin can induce degradation of a constitutively expressed target 
 
To demonstrate the ability of degradins to constitutively knock-down a specific 
target, scFv9E1-degradin was stably transfected into a HEK 293 cell line 
constitutively expressing mdα, membrane expression levels of mdα were analysed 
by cytofluorimetry and Western blotting.  
As shown in figure 15A, Western blotting analysis revealed a significantly lower 
amount of mdα in the clone stably expressing degradin (clone G6), when 
compared to the non-transfected cell line. 
An ulterior confirmation of this result came from cytofluorimetric analysis using 
either the anti FcεRI-α chain mAb 9E1 (Figure 15B) or the ligand, a purified human 
IgE (Figure 15C). 
As shown in figure 15B G6 clone showed a very strong decrease in mdα 
expression in comparison to the clone expressing only mdα; consistently also the 











The G6 cell line was maintained in culture for long periods without changes in the 
profiles of mdα expression, demonstrating that degradins can constitutively induce 
a strong and sustained target degradation. 
 
Figure 15: mdα levels on HEK 293 cells constitutively expressing mdα and scFv9E1-degradin 
Western blotting analysis using mAb 9E1 to detect mdα and anti-SV5 to detect degradin. Anti-actin 
was used as loading control. 
B and C) Cytofluorimetry on HEK 293-mdα/degradin (clone G6) stained with mAb 9E1 to detect 
mdα expression on the cellular membrane (B) or with human IgE to evaluate binding to mdα (C).  
 
To confirm that the reduced expression of mdα was the consequence of the 
degradin activity cells expressing mdα and G6 cells were treated for 6 hours with 
the proteasome inhibitor MG132. As shown in figure 16, an increased amount of 
mdα was observed in the presence of the proteasome inhibitor, thus confirming 
that the degradin-induced-degradation takes place at least in part through the 
proteolytic activity of the proteasome. 
These results indicate that the reduced expression of mdα is due a continuos 
























Figure 16: Proteasome inhibitor treatment on mdα clone and G6 clone. 20 µM MG132 treatment 
was performed for 6 hours. Anti-actin was used as loading control. 
 
The TGEV spike protein S, a second model for degradin  
 
A second model of degradins was also developed and tested. The target protein in 
this case is represented by the spike protein S of the coronavirus TGEV, while the 
S-specific degradin was obtained using as recognition moiety a scFv derived from 
mAb 6A.C3 (scFv6A.C3 324,325). 
Also in this case the control scFv6A.C3-KDEL was produced (Figure 17). 
It should be noted that S-protein is absolutely essential for the viral particle to be 
infective, yet it is not required for the assembly of the viral particle. Thus the 
scFv6A.C3-degradin/S protein model represents an ideal case in which the 
degradin directly targets a relevant biological effect.  
The BHK pAPN cell line, stably expresses the aminopeptidase N which is the 
receptor for the porcine TGEV 336 and is therefore highly permissive for viral 
infection and replication. I used this cell line to generate four different stable 
transfectants expressing the anti S protein scFv6A.C3-degradin (S-degradin), 
scFv6A.C3-KDEL (S-KDEL), irrelevant-degradin or the secretory anti-S protein 
αSIP-6A.C3 (S-SIP; Figure 18). The latter one was previously demonstrated to be 
actively secreted in the extracellular medium with a strong neutralization activity 
on virus infection (Figure 18). 
The scFv6A.C3-degradin, irrelevant-degradin and scFv6A.C3-KDEL localise in the 
ER, the first two as transmembrane proteins, while the last one is retained in the 
ER through the KDEL sequence.  
A scheme of the constructs and the corresponding stable transfectants are shown 











Figure 17: Schematic representation of constructs. A) TGEV S protein specific scFv6A.C3-degradin 





Figure 18: Intracellular localisation of the constructs transfected into BHK pAPN cell line. scFv6A.C3 
was expressed in three different version: as degradin anchored at ER membrane (S-degradin), as 
KDEL tagged localised in ER lumen (S-KDEL) and as αSIP-6A.C3 which is secreted in the 
extracellular medium (S-SIP). As a control of specificity, an irrelevant-degradin was also 




The four different cell lines and the original untransfected one (BHK pAPN) were 
then infected with TGEV. If the S-specific degradin was functional we expected a 
specific decrease in the accumulation of protein S with no alteration of the other 
viral proteins. 
As visualised by Western blotting on lysates of TGEV infected cells, scFv6A.C3-
degradin heavily impaired S protein expression, whereas N and M proteins were 
normally expressed demonstrating, once more, the specificity of the degradin. 
Thus, while the virus could infect cells leading to a normal expression of N and M 
proteins expression of S protein was heavily compromised because of degradation 
concomitantly with S-degradin expression (Figure 19), on the contrary, the 
irrelevant degradin did not affect neither S protein expression nor M and N protein 
expression. 
The scFv6A.C3-KDEL also caused a decrease in S protein expression, most likely 
through intracellular retention.  
As previously demonstrated, αSIP-6A.C3, neutralizes the virus extracellularly, thus 
inhibiting virus infection 325, clearly reflected in the reduced accumulation of all the 
three viral proteins S, N and M (Figure 19). 
 
 
Figure 19: Untransfected BHKpAPN cell line and BHKpAPN cell lines expressing the proteins 
indicated on the figure were infected with 1 M.O.I. of TGEV. Lysates were analysed by Western 
blotting. TGEV S protein expression was detected with murine mAb 1D.G3, TGEV M and N protein 
expression were detected with murine mAbs 25.22 and 3D.C10 respectively. Anti-actin antibody 





































scFv6A.C3-degradin inhibits TGEV infective particles production at 
intracellular level 
 
The yield of infective viral particles produced from the different cell lines was then 
tested in a plaque forming assay 338 by I. Sola (L. Enjuanes lab-Centro Nacional 
de Biotecnologia-Madrid 324,325) and the result obtained is shown in figure 20. 
The scFv6A.C3-degradin as well as scFv6A.C3-KDEL caused a strong reduction in 
viral titres (1-3%) compared to the irrelevant-degradin. It can be deduced that, 
because of the reduction in the production of S protein, inhibition of the formation 
of infective viral particles at the intracellular level was the consequence of the 
activity of scFv6A.C3-degradin and scFv6A.C3-KDEL. 
As expected, and as previously described, 6A.C3 soluble SIP version completely 
inhibited the formation of infective TGEV particles. Its neutralization activity 
however, takes place at extracellular level directly inhibiting the infection. 
 
 
Figure 20: Histogram of TGEV titration of supernatants of BHKpAPN stable clones. The number of 
TGEV infective particles obtained after TGEV infection of irrelevant-degradin cell line represents 



















Degradin and retro-translocation 
 
Since the proteolytic activity of the protesome was demonstrated to be essential 
during degradin-induced degradation the idea was to further characterise the 
pathway of degradation focusing on the retro-translocation process. 
Retro-translocation is an essential step during ERAD that allows the release of 
misfolded proteins from the ER to the cytosol in order to ensure their proteasome-
dependent degradation. 
Due to the absence of a specific and efficient system to detect retro-translocated 
molecules we therefore developed a method that allows direct identification of 
proteins retro-translocated from the ER to the cytosol. The system is based on the 
specific in vivo biotinylation of the protein of interest tagged with the 15 aminoacids 
long biotin-acceptor-peptide (BAP) by the E. Coli biotin ligase BirA expressed in 
the cytosol. We reasoned that if a BAP-tagged protein localised in the lumen of the 
ER is dislocated to the cytosol, it should become selectively biotinylated by the 
cytosolic BirA while, the non retro-translocated ones should not. 
In order to test the method we used as a model the human A2 allele of the MHC 
class I α chain (MHC-Iα), which has been extensively studied and described to be 
targeted by two HCMV proteins (US2 and US11) for dislocation to the cytosol and 
for proteasomal degradation. US2 and US11 carry out a degradative activity 
against MHC-Iα molecules with the aim of escape the host immune system 98,235. 
In order to confer to MHC-Iα the possibility to become biotinylated an engineered 
version of MHC-Iα fused with a BAP peptide at the amino-terminal side was 
designed. Since MHC-Iα molecule is a type I transmembrane protein with an ER 
luminal N-terminal portion, when the BAP peptide is inserted at the N-terminus it 
should be accessible to the cytosolic BirA only when dislocated from the ER to the 
cytosol, by means of US2 and US11 activities.  
It has been already demonstrated that secreted and membrane proteins modified 
with the addition of the BAP peptide at the N-terminus, due to their insertion in the 
ER during translation, cannot get biotinylated by cytosolic BirA (cyt-BirA) but they 




The BAP-MHC-Iα chain was therefore engineered by fusing at the N-terminus of 
the sequence the 12 aminoacids long SV5 tag to allow recognition by an anti-SV5 
antibody followed by the 15 aminoacids long BAP peptide (Figure 21A). 
The BAP peptide of the resulting BAP-MHC-Iα would be completely inserted in the 
ER lumen and would be recognised by cyt-BirA only upon retro-translocation to 
the cytosol. 
Once in the cytosol, the BAP peptide should be rapidly recognised by cyt-BirA 
resulting in the covalent addition of a biotin molecule to a lysine within the BAP 
sequence. 




Figure 21: A) schematic representation of the engineered version of MHC-Iα chain. BAP-MHC-Iα 
contains a secretion signal (sec) upstream the SV5 and BAP peptide encoding sequences 
B) Schematic representation of retro-translocation induced by US2 or US11. MHC-Iα molecules 







Gel retardation assay to monitor biotinylation  
 
In order to discriminate biotinylated molecules from the non-biotinylated ones, a 
gel retardation assay, illustrated in figure 22, was used. 
The assay is based on a Western blotting retardation of the biotinylated molecules 
upon incubation with streptavidin. Non-biotinylated molecules do not bind to 
streptavidin, whereas biotinylated ones bind strongly streptavidin, giving rise to a 
complex with higher molecular weight, which is resistant to SDS-PAGE conditions 
and can therefore be visualised in Western blotting as a slower migrating band. 
 
 
Figure 22: Gel retardation assay scheme. Efficiency of biotinylation can be detected by Western 
blotting analysis using the specific antibody for the protein whose biotinylation status is under 
investigation. 
The scheme represents the four possible outcomes of biotinylation and subsequent incubation of 
the sample with streptavidin. 
A. protein non-biotinylated and not incubated with streptavidin 
B. protein biotinylated but not incubated with streptavidin  
C. protein non-biotinylated and incubated with streptavidin 
D. protein biotinylated and incubated with streptavidin  
 
 
Retro-translocation of BAP-MHC-Iα  
 
A three-plasmids transient transfection was performed in HEK 293 T cells with 
plasmids encoding BAP-MHC-Iα, cyt-BirA, and one of the two immunoevasins 







A. B. C. D.
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Total lysates of the transfected cells were then incubated in the presence or 
absence of streptavidin and loaded on SDS-PAGE in order to perform the SDS-
PAGE retardation assay using anti-SV5 (tag) antibody in Western blotting. 
As shown in figure 23A, BAP-MHC-Iα expression is decreased, as expected when 
cotransfected with either US2 or US11. The decrement with US2 is less 
pronounced than with US11. Interestingly, a significant portion of BAP-MHC-Iα still 
present in cells expressing US2 and US11 was biotinylated, as visualised by the 
presence of the retarded band, indicating exposure to the cytosol. 
In contrast, in the absence of immunoevasins, only a slight amount of BAP-MHC-
Iα was biotinylated possibly representing misfolded molecules that become 
substrates of ERAD. 
To further validate the in vivo biotinylation system in the study of retro-
translocation, an experiment was performed using a US11 mutant, US11Q192L, 
which is still able to bind MHC-Iα molecules but is not able to induce their 
degradation because of the disruption of its interaction with Derlin-1 98,343. For 
these reasons US11 Q192L represents an excellent control of the specificity of the 
in vivo biotinylation system when compared to the US11 activity.  
As shown in figure 23B, US11Q192L was unable to induce BAP-MHC-Iα retro-
translocation, as demonstrated by the almost complete absence of BAP-MHC-Iα 
biotinylated molecules. On the other hand, also in this case US11 expression 
allowed the biotinylation of a high rate of BAP-MHC-Iα molecules. 
This result strongly suggests that in vivo biotinylation of luminal BAP-tagged 
proteins is a valid method to monitor retro-translocation from the ER to the cytosol. 
 
The same result was obtained following immunoprecipitation with the anti-SV5 
antibody of extracts from cells labelled with [35S]-Methionine in pulse-chase 
experiments. The advantage of this experiment resides in the fact that molecules 
produced during the pulse period can be followed during the chase period in 
which, the [35S] labelling is stopped, by the incorporation of cold methionine. 
As shown in figure 23C, after 30 minutes of [35S]-Methionine pulse, BAP-MHC-Iα 
amounts were decreased when cotransfected with US2 encoding plasmid with a 
fraction of molecules becoming biotinylated. 
Results 
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Following the chase period of two hours, a decrease in the amount of BAP-MHC-
Iα when coexpressed with US2 became more evident, due to the proteasome-
dependent degradation of the molecules produced during the pulse period. 
Although the amount of retro-translocated/biotinylated molecules was much 
reduced, a significant relative increase with respect to the non-biotinylated ones 
was observed in the presence of US2. Moreover, the biotinylated amount of 
protein was much increased compared to the non biotinylated ones (Figure 23C) 
indicating that during the chase period dislocation and degradation of the 
molecules previously produced continue to take place. 
The decrease of BAP-MHC-Iα observed after the chase period in control 
transfection without US2 (pcDNA3 mock) must be ascribed to protein turnover and 
spontaneous degradation of misfolded proteins. Indeed, the majority of the 
intracellular BAP-MHC-Iα present after the chase in cells expressing US2 are 
already delocalised to the cytosol, as evidenced by the relative intensity of the 
retarded and non-retarded bands. 
It is important to note that our method allows to detect retro-translocated 
molecules which is otherwise impossible. Indeed, the other systems used to 
discriminate luminal from dislocated molecules needs the addition of proteasome 
inhibitors. In those conditions the accumulation of retro-translocated molecules 
can be visualised because cytosolically localised proteins become deglycosylated 
by the enzyme PNGase producing a lower molecular weight band. However, we 
have obtained that even in the presence of MG132, the deglycosylated molecules 






Figure 23: A) Gel retardation assay was performed on extracts of HEK 293 T cells transfected with 
plasmids encoding BAP-MHC-Iα, cyt-BirA and one of the following proteins: US2, US11 or an 
irrelevant protein (pcDNA3 mock). Cellular lysates were incubated or not with streptavidin and 
loaded on SDS-PAGE. Western blotting was performed using anti-SV5 mAb. 
B) BAP-MHC-Iα biotinylation was compared between cotransfection with US11 or with the US11 
mutant, US11Q 192 L 
C) S35 pulse-chase experiment. HEK 293 T cells well labeled with [35S]-Methionine and 
immunoprecipitated with mAb anti-SV5. Immunoprecipitated samples were incubated or not with 
streptavidin and loaded on SDS-PAGE. 
 
As a consequence of retro-translocation of BAP-MHC-Iα induced by US2 or US11, 
dislocated molecules become substrate of the proteasome. 
The proteasome inhibitor MG132 was used to further confirm that biotinylation 
takes place only on dislocated molecules. Up to now retro-translocation of BAP-
MHC-Iα molecules has been studied through the detection of deglycosylated 
molecules in the cytosol when the proteasome is inhibited 235. 
As shown in figures 24, when coexpressed with either US2 (24A) or US11 (24B) 
BAP-MHC-Iα degradation was reduced and the amount of biotinylated (retro-
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In our cells, very few deglycosylated molecules accumulated after proteasome 
inhibition compared to previous works 235, in particular when coexpressed with 
US11 (Figure 24A), while these molecules are more represented in the presence 
of US2 (Figure 24B).  
As expected for cytosolic localised proteins, practically all deglycosylated MHC-Iα 
molecules get biotinylated, but also a significant amount of non-deglycosylated 
ones was also biotinylated. 
After proteasome inhibitor treatment the biotinylation of BAP-MHC-Iα molecules 
increased in all cases, when expressed with US2 or US11 but also when 
coexpressed with an irrelevant protein. 
This suggests that proteasome inhibition caused an increase in spontaneous retro-
translocation rate, possibly through the activation of the UPR, which increases the 
expression of proteins involved in the retro-translocation and therefore would 
increase the efficiency of the process.  
As concluding remark the analysis of retro-translocated molecules by in vivo 
biotinylation allowed us to detect also biotinylated molecules that bear a normal 
glycosylation, confirming its higher efficiency and the possibility to detect retro-
translocation in the absence of proteasome inhibitor. 
This result also indicates that deglycosylation takes place after dislocation and is 
the rate limiting step. In other words, as soon as deglycosylated, dislocated 
molecules are rapidly degraded by the proteasome and can accumulate only upon 


















Figure 24: HEK 293 T cells were transfected with plasmids encoding BAP-MHC-Iα, cyt-BirA either 
with US2 (A) or with US11 (B) or with pcDNA3 mock. Cellular lysates were incubated or not with 
streptavidin and loaded on SDS-PAGE. MHC-Iα detection was performed using anti-SV5 mAb. As 
loading control anti-actin antibody was used. 
 
Quantification of BAP-MHC-Iα  retro-translocated molecules  
 
One important aspect of our new method to detect retro-translocated molecules is 
that it allows the quantification in a precise and easy way.  
Quantification was performed by ELISA as shown in figure 25A; BAP-MHC-Iα 
molecules were captured with mAb anti-SV5, and biotinylated molecules were 
detected using HRP-conjugated streptavidin. 
As shown in histogram of figure 25B the amount of BAP-MHC-Iα biotinylated 
molecules was much higher in the presence of US2 or US11 compared to pcDNA3 
mock transfection. 
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Proteasome inhibitor treatment caused an increase of biotinylated BAP-MHC-Iα 
molecules amount, either when coexpressed with US2 or US11, or with an 
irrelevant protein (pcDNA3 mock). 
This suggests, in agreement with Western blotting results, an increased rate of 
retro-translocation due to UPR activation caused by proteasome inhibition, which 
leads a higher amount of BAP-MHC-Iα to reach the cytosol where it gets 
biotinylated.  
 
Figure 25: A) Schematic illustration of ELISA assay to detect biotinylated BAP-MHC-Iα molecules 
B) ELISA assay performed in triplicate and O.D: measurements were plotted in a histogram. 
 
 
Degradins induce retro-translocation of target substrates 
 
Since the in vivo biotinylation system demonstrated to be an important tool to 
monitor retro-translocation we wanted to exploit the method to study the 
mechanism of degradation induced by degradins. 
For this purpose we used sα-SV5-BAP, a soluble version of FcεRI-α chain in 
which an SV5 tag and a BAP peptide were added at the C-terminus (αD1D2-SV5-
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As shown in figure 26B, and similarly to what observed for sdα, when coexpressed 
with scFv9E1-degradin only a small portion of sα-SV5-BAP could reach the 
extracellular medium and when coexpressed with scFv9E1-SEL1LΔ the inhibition of 
secretion was almost complete. 
Interestingly, as shown in figure 26C, all the intracellular sα-SV5-BAP present in 
cells expressing the irrelevant-degradin or scFv9E1-degradin was biotinylated, 
indicating their cytosolic localisation. However, the intracellular material found with 
the irr-degradin represents only a small fraction since most of it was secreted 
suggesting an active role of retro-translocation and degradation. 
On the other hand, the scFv9E1-SEL1LΔ, massively retained sα-SV5-BAP in the 
ER, with only a small fraction getting biotinylated, thus confirming the important 
role of 402-773 SEL1L residues for the retro-translocation process. Of note, 
biotinylation was total for the deglycosylated sα-SV5-BAP and only partial (about 
20%) for the glycosylated molecules. 
While more than 90% of sα-SV5-BAP molecules are already deglycosylated when 
coexpressed with scFv9E1-degradin only a small fraction of these molecules was 
shuttled to the cytosol and deglycosylated when coexpressed with scFv9E1-
SEL1LΔ and, as expected all deglycosylated molecules get biotinylated. 
In addition is noteworthy the inability of the secreted sα-SV5-BAP molecules to get 

















Figure 26: A) Schematic representation of sα-SV5-BAP, the FcεRI-α chain soluble version with an 
SV5 tag and a BAP at the C-terminus.  
B-C) In vivo biotinylation was performed on an SV5-BAP version of sdα: sα-SV5-BAP to study 
retro-translocation induced by scFv9E1-degradin. 
sα-SV5-BAP was expressed in HEK 293 T cells with cyt-BirA and the proteins reported on the 
figure. Secretion of sα-SV5-BAP was analysed on supernatants (B) and the biotinylation on cellular 
lysates (C). Lysates were therefore loaded on SDS-PAGE upon incubation in the presence or 




In vivo biotinylation of sα-SV5-BAP was also performed with the LFcε-degradin. 
As shown in figure 27A also sα-SV5-BAP secretion was almost completely 
blocked by LFcε-degradin and slightly impaired by LFcε-SEL1LΔ whereas, the 
deleted ligand degradin (LFcεΔ-degradin) did not affect the secretion. 
Intracellular biotinylation of sα-SV5-BAP takes place in a considerable manner 
when coexpressed with LFcε-degradin either on glycosylated or on deglycosylated 
molecules. When coexpressed with SEL1LΔ only a fraction of the total sα-SV5-











Figure 27: In vivo biotinylation was performed on sα-SV5-BAP to study retro-translocation induced 
by LigandFcε-degradin. 
sα-SV5-BAP was expressed in HEK 293 T cells cyt-BirA and the proteins reported on the figure. 
sα-SV5-BAP secretion was analysed in the supernatants (A) whereas biotinylation was detected on 
cellular lysates (B). Lysates were loaded on SDS-PAGE upon incubation in the presence or 
absence of streptavidin. sα-SV5-BAP detection was performed using anti-SV5 mAb (B). 
 
 
We then studied the effect of proteasome inhibition during ER-to-cytosol 
dislocation of sα-SV5-BAP induced by degradins.  
For this purpose a coexpression of sα-SV5-BAP, cyt-BirA and degradins 
(irrelevant, scFv9E1-degradin and LFcε-degradin) was performed in HEK 293T cells, 
treated 16 hours after transfection cells were with 20 µM MG132 for 6 hours. 
As shown in figure 28A the secretion of sα-SV5-BAP was strongly affected by both 
scFv9E1-degradin and LFcε-degradin.  
Proteasome inhibitor treatment did not cause accumulation of sα-SV5-BAP in the 
extracellular medium neither when coexpressed with the irrelevant-degradin nor 
when coexpressed with the specific LFcε-degradin. 
This is consistent with the fact that, in the particular case of the soluble version of 
FcεRI-α chain, MG132 blocks degradation of already retro-translocated molecules 
not affecting dislocation itself. 
Indeed upon MG132 treatment, accumulation of sα-SV5-BAP was observed 
intracellularly mainly in the deglycosylated form. As expected these deglycosylated 
molecules were completely biotinylated regardless whether cell were treated or not 
with MG132.  
Results 
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In contrast following MG132 treatment also the non-deglycosylated molecules 





Figure 28: In vivo biotinylation was applied to study retro-translocation of target molecules induced 
by degradins, on an SV5-BAP version of sdα: sα-SV5-BAP during proteasome inhibitor treatment. 
sα-SV5-BAP secretion was tested by Western blotting on supernatants (A). Biotinylation was 
analysed on extracts of HEK 293 T cells treated and not treated with MG132 and incubated or not 
with streptavidin and analysed by Western blotting (B). 
 
 
To conclude, the degradin system turned out to be a very specific and efficient 
method to induce degradation of particular targets. In order to induce specific 
degradation of a protein either antibody fragments or ligands can be used, but also 
the specificity of peptides for particular targets could be exploited. 
As expected target degradation induced by degradins occurs through the retro-
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The degradin system 
 
In the present thesis a new system to induce knock-out of proteins within the 
secretory pathway is presented. It allows to specifically induce degradation of 
particular targets within the ER. 
This protein knock-out system is based on the activity of molecules, named 
degradins, that result from the fusion between two different protein moieties, one 
with target recognition activity and the other one with degradative activity. The 
target recognition moiety could be represented by whichever target specific 
binding peptide, antibody fragment, ligands or receptors but could be also a 
partner protein that specifically interacts with the target. 
To induce degradation of the target through the proteasome machinery I wanted to 
exploit the activity of proteins involved in ERAD 344 and in particular those proteins 
that create a link between substrate recognition within the lumen of the ER and 
retro-translocation. 
The protein selected was SEL1L, involved in substrate recruitment to the ubiquitin 
ligase HRD1 179. 
SEL1L has been defined as an adaptor protein that is able to recruit the substrate 
and to bind both the ubiquitin ligase HRD1 and the putative retro-translocation 
channel Derlin-1. Thus, SEL1L creates a link between recognition of the substrate 
and its retro-translocation. 
By multiple alignment of SEL1L sequence with those of its homologues from yeast 
and C. elegans, Hrd3p and SEL1, we identified a C-terminal luminal portion of 
SEL1L sharing similarities with the Hrd3p and SEL1 luminal regions described to 
interact with the ERAD machinery; the region 402-end portion of SEL1L was 
therefore chosen as the degradative moiety. 
The choice of this SEL1L fragment was afterwards supported by the 
demonstration of the essential role of 373-end SEL1L fragment during ERAD 183. A 
fine mapping of the SEL1L region essential for protein degradation could lead to 
the definition of a smaller degradative moiety of degradins.  
SEL1L contains several domains: among them, the proline rich and the Hrd3p-like 
motifs, whose essential role during ERAD has been already demonstrated 183, are 
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maintained in degradins. The fibronectin type II domain on the contrary is missing 
in degradins and it has been already demonstrated to be dispensable for SEL1L 
activity during ERAD. It has been proposed to bind to chaperones or misfolded 
proteins or alternatively it is involved in the recruitment of other target recognition 
proteins such as EDEM or OS-9 181. 
SEL1L contains in addition several domains: the SEL1-like repeats (TPR repeats). 
The TPR domain is arranged in antiparallel amphipatic α-helices that help proteins 
interaction and multiprotein complexes assembly 182, in fact it has been associated 
with protein-protein interaction and in the recruitment of proteins in several 
processes. Degradins contain an almost complete SEL1-like repeats (TPR) cluster 
II and a complete TPR cluster III and, through the addition of a target recognition 
moiety, they are able to induce both dislocation and proteasome-dependent 
degradation of the target.  
 
Approach for testing the activity of degradins 
 
To validate the degradin system we chose two different target models; the first one 
was represented by the FcεRI-α chain and gave us the opportunity to test the 
system either on a soluble or on a membrane version of the same molecule; in 
addition it could be targeted by two types of binding moiety, the ligand (IgE) or a 
specific scFv. The second model was the TGEV spike protein S, that allowed a 
direct analysis of degradin activity on a biological property, in this case viral 
infectivity. 
The choice of FcεRI-α chain gave me the possibility of testing degradins on two 
minimal receptors constituted by the extracellular D1 and D2 domains of FcεRI-α 
chain in a secreted (sdα 332) or membrane form (mdα, Vangelista, Cesco Gaspere 
unpublished work) and was facilitated by the availability in the lab of mAb 9E1 
specific for FcεRI-α chain and its derived scFv9E1, as well as different versions of 
the ligand, IgE. 
The possibility to test degradin activity on the same molecule with or without a 
membrane anchor, allowed me to validate the system for any kind of molecule in 
transit through the ER, whether secreted or membrane bound, and to analyse if 
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there were differences between the behaviours of soluble and membrane proteins 
during degradin-induced degradation or during the ERAD pathway in general. 
By exploiting the well documented activity of the αSIP-6A.C3 (derived from the 
neutralizing anti-S protein mAb 6A.C3) in inhibiting TGEV infective particles 
formation 325, the TGEV S protein was also a good candidate to validate the 
degradin system in blocking at the intracellular level the formation of infective viral 
particles. 
Using as recognition moieties the scFv9E1 and the truncated Fcε version (domains 
εCH3 and εCH4) it was possible to obtain two different degradins specific for 
FcεRI-α chain (scFv9E1-degradin and LFcε-degradin), whereas for the anti-S 
degradin the construct was based on the scFv6A.C3 (scFv6A.C3-degradin). 
Both scFv9E1-degradin and LFcε-degradin were well expressed and, as verified by 
cytofluorimetric analysis, localised intracellularly.  
The presence in the SEL1L sequence of two sites of N-glycosylation at positions 
411 and 587 maintained in the SEL1L 402-end fragment of degradins allowed to 
perform an endoglycosydase treatment to study their localisation. The sensitivity to 
endoglycosydase H treatment indicated that degradins were primarily localised in 
the ER compartment, without reaching the Golgi. This complete ER localisation of 
degradins is likely due to signals localised in the transmembrane and cytosolic 
portions (residues 717 to 773) of SEL1L 
(http://www.uniprot.org/uniprot/Q9UBV2.html). This signal is also conserved in the 
degradin versions completely lacking the luminal region of SEL1L (SEL1LΔ), 
consistently with the effect of target retention at the ER level obtained by both 
scFv9E1-SEL1LΔ and LFcε-SEL1LΔ. 
 
The activity of degradins is target specific 
 
By testing the activity scFv9E1 and LFcε-degradins on sdα and mdα expression, I 
could show that both degradins induced efficiently a decrease of either soluble or 
membrane proteins in transit through the ER, blocking almost completely their 
secretion or membrane expression with no intracellular retention. 
The degradin activity was dependent on the specific interaction with the target and 
the recognition moiety; both irrelevant-degradin and LFcεΔ-degradin did not block 
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either sdα secretion or mdα expression at the cell surface confirming the 
specificity of the system. 
In the case of the irrelevant-degradin only a slight decrease in both mdα and sdα 
expression was observed. It is possible that this was the consequence of the 
residual activity of the SEL1L 402-end fragment in recognising misfolded proteins 
In this context the decrease observed could be due to the enhanced degradation 
of the fraction of molecules that were present in a misfolded state and that were 
not completely recognised by the ERAD machinery in conditions of proteins 
overexpression. In fact a clear difference between irrelevant and specific 
degradins was always visualised.  
Alternatively, the SEL1L 402-end fragment could induce, by sequestering SEL1L 
ER partners, an UPR response that would increase misfolded protein recognition 
and inhibit protein translation.  
 
The experiments with cycloheximide and [35]S-Methionine pulse-chase 
experiments suggest a decreased stability of mdα when expressed with the 
specific scFv9E1-degradin. Therefore it is likely that degradins are able to actively 
induce specific target degradation upon substrate recruitment by their recognition 
moiety. 
 
In addition the stability of degradins in the presence or absence of the target was 
investigated as well. 
Degradins expression was only slightly affected by the presence of the target, 
indicating that degradin upon recognition of the target is in a small fraction 
degraded it-self. Nevertheless, degradins persistence seems to be higher than its 
target suggesting the possibility to act on several target molecules before getting 
degraded.  
 
Degradation versus retention induced by degradins  
 
When compared to the intrabody bearing a KDEL signal (scFv9E1-KDEL) 
degradins demonstrated higher efficiency in inhibiting sdα secretion. The effect of 
incomplete retention of sdα by scFv9E1-KDEL could be explained by the presence 
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of scFv9E1-KDEL also in the supernatants; this could reflect an oversaturation of 
the KDEL receptor. Therefore, the excess scFv9E1-KDEL expressed would be free 
to proceed to the secretory pathway and to reach the extracellular medium. 
The scFv9E1-KDEL as well as the two constructs that produce retention (scFv9E1-
SEL1LΔ and LFcε-SEL1LΔ), displayed a modest degradative activity on both sdα 
and mdα when compared to the specific degradins (scFv9E1-degradin and LFcε-
degradin). This modest degradative activity could be the consequence of the 
induction of ER stress due to the overload of proteins in the ER (in this case the 
target proteins) which cannot be secreted or expressed on the cell surface but, 
instead, remain largely accumulated in the ER compartment. 
Using SEL1LΔ degradins the essential role of the SEL1L moiety in the induction of 
degradation was further confirmed. 
Therefore, degradins act, as expected, through the specific recognition of the 
target molecule and by inducing its degradation through the SEL1L moiety. 
Although there are some cases in which a KDEL intrabody could be sufficient to 
efficiently inhibit the target protein expression (as obtained for TGEV S protein, 
see ahead), in other cases they produce ER retention, while degradins do not. 
By producing a stable transfectant of scFv9E1-degradin in a cell line already 
expressing mdα, it was possible to obtain a continuous protein knock-out system, 
stable in time.  
This result was important because it confirmed that the effect in decreasing target 
expression was neither correlated to cell viability, nor to the altered expression of 
one of the two transiently cotransfected plasmids. 
 
Degradation induced by degradins is achieved through the proteasome 
machinery 
 
The involvement of the proteasome in the degradin-induced degradation was 
confirmed by the experiments performed in the presence of proteasome inhibitors. 
During MG132 treatment a good but not complete rescue of target protein 
expression was observed. This result indicated the involvement of the 
proteasome, at least in part, in the degradation of the target, but did not exclude 
the possible involvement of autophagy. In particular autophagy can be activated 
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during conditions of ER stress caused by proteasome inhibition. Autophagy 
induction could therefore allow a partial degradation of ERAD substrates with a 
compensatory effect that the cell exploits to avoid death 342.  
The proteasome inhibition led to an increase of both partially and Golgi-dependent 
glycosylated mdα molecules. The completely glycosylated mdα molecules 
possibly originate following accumulation caused by MG132 treatment. Once 
accumulated, a fraction of mdα molecules not involved in any binding, would be 
released to the secretory pathway and therefore free to acquire a Golgi dependent 
glycosylation. On the contrary, only deglycosylated FcεRI-α chain soluble 
molecules that have been likely already retro-translocated to the cytosol 
accumulated during MG132 treatment. Deglycosylated FcεRI-α chain soluble 
molecules are very poorly represented in the absence of proteasome inhibitors, 
most likely because they are immediately degraded. 
This notion was confirmed using the SV5 tagged soluble version of FcεRI-α chain 
that could be very efficiently detected using the anti-SV5 antibody. On the 
contrary, using sdα, the detection of these molecules could not be achieved 
because of the low sensitivity of mAb 9E1 in recognising FcεRI-α deglycosylated 
molecules. 
Cytosolic deglycosylation is a step that takes place before the entry of the 
substrate within the proteolytic chamber of the proteasome and is required for an 
efficient degradation upon substrate dislocation from the ER to the cytosol. 
Soluble proteins, probably because free from any kind of membrane anchor or 
constraint, seem to be dislocated to the cytosol very fast and, once in the cytosol, 
immediately deglycosylated and degraded, thus explaining why they were the only 
kind of molecule that accumulate during proteasome inhibition. The retro-
translocation process is still functional during proteasome inhibition and leads to 
the dislocation of the soluble SV5 tagged FcεRI-α chain molecules in the cytosol. 
Since no proteasomal degradation takes place, the dislocated deglycosylated 
molecules accumulate. 
Consistent with previous reports the rapid degradation of deglycosylated 




The finding that glycosylated mdα molecules (but not sdα) increased during 
proteasome inhibition may suggest that in the particular case of FcεRI-α, the 
membrane version (mdα) requires a functional proteasome for its extraction from 
the ER membrane whereas the soluble one (sdα) does not. This result also 
suggests different mechanisms operating for membrane and secretory proteins.. 
This hypothesis is supported by previous works in which it has been demonstrated 
that membrane proteins, for example MHC class II molecules, require an intact 
proteasome for their dislocation to the cytosol 345,346. 
 
 
Degradins and their ability in inhibiting TGEV infective particles formation 
 
Very promising results were obtained with the experiments on the TGEV virus, 
which represents the second model used to test our degradin knock-out 
technology. 
Since the absolute requirement of the TGEV spike protein S for virus infection was 
already demonstrated, we focused on a degradin containing a target recognition 
moiety specific for the TGEV S protein derived from a well characterised mAb 
(6A.C3). 
I observed that in the TGEV S protein model the scFv6A.C3-degradin and the 
intrabody scFv6A.C3-KDEL were equally efficient in inhibiting S protein expression 
and infective viral particles formation. 
This inhibition, in contrast to what previously described 325, did not imply 
extracellular neutralization of infection but impaired the intracellular assembly of 
infective particles. 
The use of TGEV spike protein S as a model highlights the possibility to use 
degradins to directly influence a biological property such as viral infectivity. 
Moreover, these experiments suggested a wider applicability of degradins 
confirming their ability to work in cells constitutively expressing them and 
suggesting their possible use in vivo.  
The intracellular inhibition of infective viral particles formation could represent an 
important application of the degradin system opening the possibility to induce 
degradation of proteins essential for viral infectivity in other systems. For instance, 
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degradins could prove useful to block virus spreading in chronic infections such as 
HIV or HCV. HIV infected patients are characterised by very long lasting infections 
in which the morbidity is caused by the immunodeficiency arising from CD4+ T 
cells depletion. Thus degradins could avoid infection of the residual fraction of 
CD4+ T cells blocking the onset of the immunodeficiency. 
 
Comparison between the degradin technology and other knock-out systems 
 
From all these evidences we can therefore draw the conclusion that the degradin 
protein knock-out technology can be applied on targets in transit through the ER or 
ER resident, against which a target recognition moiety is available. The pathway of 
degradation induced by degradins exploits at least in part the activity of the 
proteasome, although the participation of autophagy was not investigated. 
However, independently of the degradative pathway, the degradin system 
represents a novel tool for the induction of specific target proteins degradation with 
some interesting features. 
It acts at the protein level; it makes possible to use antibodies that confer very high 
specificity but also ligands, peptides whichever antibody fragment or specific 
interacting partner able to specifically recognise the target, theoretically making 
possible degradin application to a wide number of targets. 
The interesting aspect of degradins reside in their easy manipulation; it could be 
possible to construct degradins with multiple copies of the same target recognition 
moiety or with different target recognition moieties against the same protein, in 
order to increase even more the efficiency of the system.  
At the same time, recognition moieties with different specificities could be used in 
order to degrade proteins acting in different steps of the same pathway and 
therefore efficiently inhibiting that pathway. Using different recognition moieties, 
the degradation of a multiprotein complex could be achieved. 
In this context degradins with two different scFv moieties fused through a linker 
(bispecific scFv) could be used. 
Through a careful choice of the immunogenic peptide, the production of antibodies 
either highly specific for the target or directed against a domain conserved 
between different proteins could be obtained. Depending on the purpose the 
knock-out of several proteins of a particular family could be required, for example 
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with the aim of inhibiting a process carried out by proteins that share a redundant 
function. 
 
Up to now, several methods have been developed to induce specific protein 
knock-out: among others, they include intracellular antibodies and RNA 
interference.  
Antibody usage at intracellular level has been favoured by the development of 
recombinant proteins based on the use of antibody fragments such as the scFv 
302. 
They have been particularly useful in the development of techniques to isolate 
those antibodies that are able to fold also in cytosolic reducing conditions 
310,311,347,348. 
Since intrabodies can be further modified in order induce a particular cellular 
localisation, the inhibition of the target can be achieved either by directly 
neutralizing the target activity or by diverting the target into a different cellular 
compartment, blocking its secretion or membrane expression 349,350. In some 
cases, however target relocalisation using intrabodies was not achieved; for 
instance coexpression of the target and the intrabody, harboring a signal for a 
particular intracellular localisation, can cause a relocalisation of the intrabody at 
the site of target expression and not vice versa 351. 
Intrabodies could be very useful for the recognition of proteins with aberrant 
conformations since it is possible to obtain antibodies specific for a particular 
conformation. 
For example, they have been successfully used against the amyloid precursor 
protein (APP) involved in Alzheimer disease avoiding its appearance on the cell 
surface 352, against PrPc protein, by avoiding its conversion to the PrPsc aberrant 
conformation 353 and against the mutated Huntingtin protein in Huntington disease, 
by reducing aggregates formation 354. 
The degradin system offers the great advantage of actively degrade the target, no 
intracellular accumulation or target relocalisation are induced thus avoiding the 
possible formation of toxic aggregates within the cell.  
 
In the latest years much interest has been raised by the RNA interference 
technology. This technology efficiently induces protein knock out acting at the 
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mRNA level through a 19-21 base pair long double strand RNA (dsRNA), which 
leads, through its association with the RISC complex, to target mRNA degradation 
355. 
Nevertheless, the presence of off-target effects could be considerably high due to 
the possible redundancy of the target mRNA sequence. Additional limits of the 
RNA interference technology reside in the inability in discriminating between 
different conformations of the same protein and the inability to act on proteins 
already expressed or, on proteins that come in contact with the cell from the 
external environment, such as bacterial proteins and toxins. Another disadvantage 
emerges in situations where the target protein originates from a single nucleotide 
mutation; in this case the RNA interference should act at the site of the mutation 
which could be not accessible by the RISC complex and in addition it could not 
efficiently discriminate between the wild type and the mutated mRNA. In many of 
these cases degradins could instead be functional. 
It is interesting to mention some protein knock-out systems that have been 
previously described. One of them was based on the construct of a fusion protein 
between a chemokine and the cytosolic fragment derived from the HIV protein 
Vpu. In this way specific degradation of the chemokine receptor was reported 356. 
A different approach for degradation of cytosolic proteins has been described: the 
suicide (or silencing) intrabody technology (SIT). This approach exploits the TNF-
dependent-degradation of the inhibitory protein IkBα, which has been fused to an 
intrabody specific for a particular target. The resulting suicide intrabody is 
degraded by the proteasome together with the degradation of its target 357.  
A different strategy to obtain knock-out of cytosolic proteins was based on the 
activity of subunits of the cytosolic SCF ubiquitin ligase complex, named Fbox-
containing proteins. These proteins act as adaptors between the substrate and the 
cytosolic ubiquitin ligase Skip1. The F-box containing proteins modified by the 
addition of a moiety specific for the target were able to induce degradation of the 
chosen target protein 358. 
 
As mentioned above for intracellular antibodies an aspect that makes our system a 
very promising way to obtain specific protein knock-out is represented by the 
possibility to act on a particular protein conformation. A number of human 
diseases are caused by single point mutations that could be hardly discriminated 
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by specific siRNAs molecules, but that can deeply change protein conformation, 
which could be, instead specifically recognised by a monoclonal antibody. 
The possibility to use conformational antibodies could confer to degradins the 
unique possibility to discriminate between aberrant and proper conformations, 
inducing degradation of only the aberrant one. Moreover, there are even cases 
where the aberrant conformation originates without the presence of point 
mutations such as in the Creutzfeld-Jacob disease caused by prions. 
Proteins bearing an aberrant conformation can produce aggregates with toxic 
effects for the cells; neurodegenerative disorders are likely the most attracting 
class of protein aggregation-related diseases such as Alzheimer disease (AD), 
one of the most frequent disorders in aging population 359. 
AD is accompanied by the formation of neuritic amyloid plaques, neurofibrillary 
tangles and neuropil threads. It involves the excessive formation of a product of 
the amyloid precursor protein (APP) metabolism: the amyloid β peptide 1-42 (Aβ1-
42). This results in Aβ1-42 accumulation in the neuronal ER and at extracellular level 
359,360. Pathogenesis of AD seems to be indeed correlated with the conversion of 
natural monomer to toxic oligomers 361,362. 
The Transmissible Spongiform Encephalopaties (TSE) class of diseases is 
another example of how conformational changes can subvert a normal phenotype 
to a pathological phenotype. TSEs are caused by a very peculiar infective agent, 
the prion, which is an autocatalitically replicating proteins 363 responsible of BSE, 
Creutzfeld-Jacob disease and Scrapie 364. 
The protein involved is Prpc that undergoes conformational modification by 
mechanisms so far poorly understood, giving rise to an insoluble version of the 
protein named PrpSC . 
There are reports that show the activity of the proteasome in clearing aggregated 
proteins, even inclusions, when the production of the abnormal protein is stopped 
365. Therefore, degradin technology could be used not only to avoid protein 
aggregation of newly synthesised proteins, but also in clearing pre-existing 
aggregates. Intrabodies, which have demonstrated to reduce protein aggregates, 
due to their lower efficiency in inhibiting protein expression could be less efficient 
than degradins on pre-existing aggregates. Thus theoretically, degradins could be 




Other possible applications of the degradin system could include the inactivation of 
bacterial antigens in transit through the ER. Bacterial pathogens, such as 
“Salmonella typhimurium” and “Chlamidia trachomatis”, are able to persist within 
the cell in intracellular vacuoles that protect the bacteria from the innate immune 
response and within these elements bacterial replication can occur 366,367. 
Although vacuoles isolate the bacteria from cellular structures, there are proteins 
released by the pathogens that get into the cellular secretory pathway. Examples 
are the “S. typhimurium” Slrp protein, possibly involved in the interference with 
MHC-I peptide presentation, due to the induction of ER stress 368 and “Chlamydia 
trachomatis” proteins and lipids (MOMP, IncA and LPS) whose trafficking through 
the ER could induce ER stress as well 369. 
In these cases the siRNA approach would not be useful, because the bacterial 
RNA does not enter the cell, while degradins act at the protein level and can 
therefore be efficient in contrasting the effects of bacterial infections. 
Degradins could also be exploited to study particular phenotypes arising from the 
knock-out of specific proteins in cell cultures but also in vivo through the delivery of 
degradins encoded by viral vectors. In addition, they could be used to target 
proteins involved in metastatic behaviour of cancer cells, such as 
metalloproteinases or cathepsins, with the aim of blocking the metastatic 
transformation of tumours. 
 
A further possible application of degradins could be the selective redirection of 
antigens to proteasome degradation in antigen presenting cells (APC), including 
dendritic cells, to increase presentation of antigen-derived peptides in order to 
activate antigen-specific cytotoxic CD8+ T-lymphocytes (CTL). CTLs are in fact 
activated by the interaction of the T cell receptor with the antigen-derived-peptides 
bound to MHC class I molecules on the surface of specialised antigen-presenting 
cells. Peptide loading on MHC-I requires antigen to be previously processed by 
the proteasome, that executes the initial antigen proteolytic degradation. The 
generated peptides are in turn transferred to the ER and loaded to class I MHC 
molecules. 
The degradin model could be exploited to efficiently generate a cytotoxic CD8+ 
response against an antigen when a specific monoclonal antibody is available: an 
antigen-specific degradin would efficiently direct the antigen towards proteasome 
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degradation and generate peptides that can be loaded to MHC I molecules and 
activate a CD8+ response. 
An antigen could also be artificially generated, even if a specific antibody is not 
available: A recombinant target for a degradin could be created by fusing the 
antigen to a different protein, against which is possible to create a specific 
degradin. Coexpression of the two constructs (target antigen and degradin) in the 
same APC cell, such as DCs, will lead to target degradation and efficient peptide 
presentation in association with MHC I molecules, thus inducing lymphocyte 
activation. The genetic constructs encoding the target and degradin could be 
administered to a patient by DNA vaccination, for example by biolistic gene 
transfer, which efficiently transfects dermal antigen presenting cells, such as 
dendritic cells and macrophages; a further level of control that these constructs are 
expressed specifically in antigen presenting cells could be achieved by having 
their expression controlled by a dendritic cell-specific promoter, such as that of 
CD11c. 
 
In vivo biotinylation as a tool for the study of retro-translocation 
 
Proteasome mediated degradation requires a step of retro-translocation from the 
ER to the cytosol: to get a better insight into the events, that following target 
recognition by degradins lead to proteasome degradation, a new method that 
allows identification of the retro-translocated molecules was developed. 
The system is based on the specific in vivo biotinylation of the protein of interest, 
which is modified by the addition of a 15 aminoacids long biotin-acceptor-peptide 
(BAP peptide). 
This peptide is specifically biotinylated by the E. coli biotin ligase BirA, whose 
expression could be directed to the cytosol of eukariotic cells (cyt-BirA). Moreover, 
as the specificity of cyt-BirA enzyme in biotinylating BAP containing molecules 
only in the cytosolic compartment was previously assessed (330, Arnoldi, 
Predonzani, Burrone Unpublished work), we expected that as soon as an ERAD 
substrate would reach the cytosol, it would immediately become substrate of the 
biotin ligase cyt-BirA resulting in the covalent addition of a biotin to the unique 
lysine residue present in the BAP peptide. 
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This system was tested to detect retro-translocation of the human MHC-Iα which 
is recognised as a well established and widely used target of retro-translocation 
induced by two HCMV immunoevasins US2 and US11.  
The in vivo biotinylation approach demonstrated to be a very efficient and specific 
system for the detection of retro-translocated molecules. With this system it was 
possible to detect a large amount of MHC-Iα molecules that get biotinylated, 
because of their dislocation to the cytosol, only in the presence of US2 and US11 
and without proteasome inhibitors. 
In previous studies retro-translocated MHC-Iα molecules were identified as 
deglycosylated cytosolic proteins 270. In addition our in vivo biotinylation method 
was able to detect a large amount of MHC-Iα molecules that get biotinylated in the 
cytosol, and therefore have undergone retro-translocation, but that are still 
glycosylated. As expected, the few deglycosylated molecules detected in the 
presence of proteasome inhibitors were completely biotinylated due to their 
cytosolic localisation. 
Thus, the in vivo biotinylation was not only able to detect all the deglycosylated 
molecules but also a large amount of glycosylated ones. We hypothesised that 
MHC-Iα glycosylated and biotinylated molecules could represent an intermediate 
state of retro-translocation; these molecules are probably still anchored to the ER 
membrane, but have already started to dislocate to the cytosol from their N-
terminus with the N-glycans localised inside the ER lumen. According to this 
hypothesis, only the MHC-Iα completely retro-translocated to the cytosol were 
found fully deglycosylated (Petris, Vecchi, Burrone. Unpublished work). 
The glycosylated and retro-translocated MHC-Iα molecules were undetectable 
using previous methods and this could have lead to an underestimation of the rate 
of MHC-Iα retro-translocated proteins. 
Since deglycosylated molecules are immediately transferred to the proteasome for 
degradation, in vivo biotinylation enables the visualisation of the proportion of 
molecules in each step of the retro-translocation and degradation processes. This 
prompted us to propose that, on the other side, the extraction of proteins from the 




An interesting finding was that treatments with proteasome inhibitors led to the 
accumulation of retro-translocated/biotinylated molecules even in the absence of 
immunoevasins, as shown by Western blotting and ELISA assays. 
The increase of retro-translocation/biotinylation during proteasome inhibition is 
likely caused by the activation of ER stress following the accumulation of 
misfolded proteins that, in turn, cause the UPR induction. The UPR, which has 
been already described to be activated during proteasome inhibition, is 
responsible of the expression of proteins involved either in protein folding, such as 
chaperones, and in ERAD, such as SEL1L and Derlin-1, in order to retro-
translocate and degrade more efficiently misfolded proteins 184. Also a more 
efficient retro-translocation could be the cause of the increased proportion of 
biotinylated and deglycosylated molecules accumulated in the cytosol. 
 
All the results obtained with the in vivo biotinylation together with the finding that in 
the cytosolic fraction MHC-Iα molecules can be detected only in a deglycosylated 
status (Petris, Vecchi, Bestagno, Burrone. Unpublished work) the finding that also 
glycosylated MHC-Iα molecules were ubiquitinylated let us to confirm a previously 
proposed model for MHC-Iα retro-translocation, which could be possibly expanded 
to all single membrane span proteins 370. 
As illustrated in figure 29, the idea is that once engaged by US2 or US11, MHC-Iα 
molecules start the retro-translocation process from their N-terminus, leading this 
portion, containing the BAP peptide to face the cytosol. The portion of the 
molecule containing the N-glycan would still be protected from the activity of the 
cytosolic PNGase because localised within the lumen of the ER. 
As soon as the BAP peptide becomes accessible to the cyt-BirA enzyme it gets 
biotinylated. The resulting biotinylated molecules still bound to the ER are 
glycosylated, whereas after extraction from the ER membrane a complete 
deglycosylation can occur in the cytosol. Since deglycosylated molecules are 
rapidly degraded, their visualisation can be achieved only in the presence of 







Figure 29: A) MHC-Iα molecules are engaged within the ER by US2/US11 immunoevasins B) 
Once engaged by US2/US11 SV5-BAP-MHC-Iα starts the retro-translocation process from the N-
terminus C) BAP peptide can come in contact with cyt-BirA in the cytosol leading to the formation 
of partially dislocated MHC-Iα biotinylated molecules D) MHC-Iα can finally reach the cytosol 




Since the in vivo biotinylation was validated also on other ERAD models (Petris, 
Vecchi, Burrone unpublished work) we have used it in the study of retro-
translocation induced by degradins. 
For this purpose we used an engineered version of FcεRI-α chain containing a 
BAP peptide, sα-SV5-BAP 330. 
When expressed with scFv9E1-degradin and LFcε-degradin intracellular sα-SV5-
BAP was biotinylated as visualised by the gel retardation assay (see figures 26 
and 27 of results chapter).  
On the other hand, when coexpressed without degradins sα-SV5-BAP was rapidly 
secreted and no retro-translocated/biotinylated molecules were visualised. 
The irrelevant-degradin however, allowed sα-SV5-BAP to be secreted but, it also 
caused a small fraction of intracellular molecules to get biotinylated. The two 
specific scFv9E1 and LFcε degradins induced very efficiently retro-




The target specific degradins most likely induce retro-translocation/biotinylation of 
the target independently on its folding state, mediated by the activity of the target 
recognition moiety. Some residual activity of the SEL1L (402-end) fragment in the 
recognition of misfolded proteins could also be present as shown by the effect of 
the irrelevant-degradin. While the intracellular amount of sα-SV5-BAP 
coexpressed with the irrelevant-degradin probably reflects the percentage of 
misfolded molecules because almost completely retro-translocated/biotinylated, 
the secreted material instead represents the correctly folded fraction suggesting 
that the ERAD machinery is not sufficient in the recognition of misfolded protein 
during overexpression conditions. 
This non complete efficiency of the ERAD machinery is supported by a previous 
work in which a fraction of the misfolded “null Hong Kong” truncated version of the 
secretory antitrypsin protein, normally non secreted and degraded by ERAD, can 
escape the ER quality control system and be secreted. However its secretion was 
completely blocked by overexpression of OS-9, a protein that in cooperation with 
SEL1L is involved in the recognition of misfolded protein 69. 
Therefore, it is possible that the 402-end SEL1L fragment can supplement the 
endogenous ERAD machinery leading to a more efficient recognition of the 
misfolded proteins. To confirm this role of the 402-end SEL1L portion, 
overexpression of this fragment should be compared with that of the wt SEL1L 
protein. To support the hypothesis SEL1L overexpression should therefore cause 
a slight decrease in mdα and sdα expression, through a more efficient degradation 
of the misfolded fraction. 
Alternatively, the effect visualised by the overexpression of the irrelevant degradin 
could be due to the induction of a UPR response as already decribed for the 
immunoevasin US11 272. 
 
Taken together all these data further confirm that degradins induce retro-
translocation of the target molecule to the cytosol where it gets deglycosylated and 
degraded. 
 




One is based on the subcellular fractionation that allows the detection of those 
proteins that after retro-translocation form the ER are localised in the cytosol. This 
technique has been very useful in the identification of deglycosylation as a step 
first demonstrated for MHC-Iα degradation, taking place in the cytosol before 
degradation 275. 
Another method is based on the detection of retro-translocated molecules, by 
cytosolic fluorescent enrichment following ER to cytosol dislocation of a GFP-
tagged protein into the cytosol 371. 
Retro-translocation was also studied by looking at the decrease of fluorescence-
labelled ERAD substrate that, when dislocated, can come in contact with a 
quencher agent and dislocation to the cytosol is measured as a decrease in 
fluorescence 202. 
All these techniques however, were able to detect retro-translocated molecules 
only in the presence of proteasome inhibitors, which leads to protein accumulation, 
favouring the detection of retro-translocated molecules. 
In vivo biotinylation offers a great advantage consisting in the possibility to easily 
detect retro-translocated molecules, independently of whether they are 
glycosylated or not, and without the use of proteasome inhibitor. 
Through the possibility to discriminate and separate biotinylated proteins from the 
non-biotinylated ones, studies about the characteristics of retro-translocated 
molecules could be carried out. 
The in vivo biotinylation turned out to be a very efficient and specific system; it can 
be exploited to study the events that bring a protein to the cytosol allowing the 
detection of all types of retro-translocated molecules. It is a simple and 
reproducible method that can be used to study the retro-translocation pathway but 
also to study the intrinsic tendency of a protein to misfold or the different tendency 
of the same protein to misfold in different tissues. In addition, since the BAP 
peptide is rather short it should not alter protein functions. 
An interesting and unresolved question that in vivo biotinylation could help to 
understand regards the temporal organisation of retro-translocation and 
ubiquitinylation processes.  
Up to now ubiquitinylation was seldom described to take place during retro-
translocation event, even before extraction from the ER membrane. Although with 
the in vivo biotinylation we were able to detect a large fraction of MHC-Iα 
Discussion 
 131 
molecules facing the cytosol during the retro-translocation process, but still 
attached to the ER membrane, no evidence of ubiquitinylation was found. The 
detection of ubiquitinylated molecules was not achieved probably because of the 
tight sequentiality of ubiquitinylation and deubiquitinylation processes. However, 
performing radioactive pulse-chase experiments it should be possible to detect the 
ubiquitinylated MHC-Iα molecules, still attached to the ER membrane that should 
get fully biotinylated.  
With the in vivo biotinylation system it could be possible to study whether the 
presence of a transmembrane domain can influence both retro-translocation and 
ubiquitinylation processes. 
Finally, since biotinylation allows the purification of retro-translocated molecules it 
can be exploited to study the modifications that take place in the cytosol and to 
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